

MR01

Particulars of a charge

Laserform

147363/13

A fee is payable with this form.
Please see 'How to pay' on the
last page

You can use the WebFiling service to file this form online.
Please go to www.companieshouse.gov.uk

☒ **What this form is for**
You may use this form to register
a charge created or evidenced by
an instrument

☒ **What this form is NOT for**
You may not use this form to
register a charge where the charge is
instrument Use form MR0



A15
07/07/2015
COMPANIES HOUSE
#49

This form **must be delivered to the Registrar for registration with 21 days** beginning with the day after the date of creation of the charge. If the form is delivered outside of the 21 days it will be rejected unless it is accompanied by a court order extending the time for delivery

☒ You **must** enclose a certified copy of the instrument with this form. This will be scanned and placed on the public record. **Do not send the original**

1 Company details

Company number 08705972

Company name in full Pro Bono Bio plc

For official use

→ **Filing in this form**
Please complete in typescript or in
bold black capitals

All fields are mandatory unless
specified or indicated by *

2 Charge creation date

Charge creation date 25/06/2015

3 Names of persons, security agents or trustees entitled to the charge

Please show the names of each of the persons, security agents or trustees
entitled to the charge

Name Knight Therapeutics Inc

Name

Name

Name

If there are more than four names, please supply any four of these names then
tick the statement below

☐ I confirm that there are more than four persons, security agents or
trustees entitled to the charge

MR01

Particulars of a charge

4

Brief description

Please give a short description of any land, ship, aircraft or intellectual property registered or required to be registered in the UK subject to a charge (which is not a floating charge) or fixed security included in the instrument

Brief description

Please submit only a short description. If there are a number of plots of land, aircraft and/or ships, you should simply describe some of them in the text field and add a statement along the lines of, "for more details please refer to the instrument"

Please limit the description to the available space

5

Other charge or fixed security

Does the instrument include a charge (which is not a floating charge) or fixed security over any tangible or intangible or (in Scotland) corporeal or incorporeal property not described above? Please tick the appropriate box

☒ Yes

☐ No

6

Floating charge

Is the instrument expressed to contain a floating charge? Please tick the appropriate box

☒ Yes Continue

☐ No Go to Section 7

Is the floating charge expressed to cover all the property and undertaking of the company?

☒ Yes

7

Negative Pledge

Do any of the terms of the charge prohibit or restrict the company from creating further security that will rank equally with or ahead of the charge? Please tick the appropriate box

☒ Yes

☐ No

8

Trustee statement ¹

You may tick the box if the company named in Section 1 is acting as trustee of the property or undertaking which is the subject of the charge

☐

¹ This statement may be filed after the registration of the charge (use form MR06)

9

Signature

Please sign the form here

Signature

Signature

X *Dating UUMSA LP* X
AS solicitor for the charger

This form must be signed by a person with an interest in the charge

MR01

Particulars of a charge

**Presenter information**

You do not have to give any contact information, but if you do, it will help Companies House if there is a query on the form. The contact information you give will be visible to searchers of the public record.

Contact name **Danielle Robinson (033015 01)**Company name **Dentons UKMEA LLP**Address **The Pinnacle****170 Midsummer Boulevard**Post town **Milton Keynes**

County/Region

Postcode **M K 9 1 F E**

Country

DX

Telephone **+44 1908 690260****Certificate**

We will send your certificate to the presenter's address if given above or to the company's Registered Office if you have left the presenter's information blank.

**Checklist**

We may return forms completed incorrectly or with information missing

Please make sure you have remembered the following

- ☐ The company name and number match the information held on the public Register
- ☐ You have included a certified copy of the instrument with this form
- ☐ You have entered the date on which the charge was created
- ☐ You have shown the names of persons entitled to the charge
- ☐ You have ticked any appropriate boxes in Sections 3, 5, 6, 7 & 8
- ☐ You have given a description in Section 4, if appropriate
- ☐ You have signed the form
- ☐ You have enclosed the correct fee
- ☐ Please do not send the original instrument, it must be a certified copy

**Important information**

Please note that all information on this form will appear on the public record

**How to pay**

A fee of £13 is payable to Companies House in respect of each mortgage or charge filed on paper

Make cheques or postal orders payable to 'Companies House'

**Where to send**

You may return this form to any Companies House address. However, for expediency, we advise you to return it to the appropriate address below

For companies registered in England and Wales:

The Registrar of Companies, Companies House,
Crown Way, Cardiff, Wales, CF14 3UZ
DX 33050 Cardiff

For companies registered in Scotland:

The Registrar of Companies, Companies House,
Fourth floor, Edinburgh Quay 2,
139 Fountainbridge, Edinburgh, Scotland, EH3 9FF
DX ED235 Edinburgh 1
or LP - 4 Edinburgh 2 (Legal Post)

For companies registered in Northern Ireland:

The Registrar of Companies, Companies House,
Second Floor, The Linenhall, 32-38 Linenhall Street,
Belfast, Northern Ireland, BT2 8BG
DX 481 N R Belfast 1

**Further information**

For further information, please see the guidance notes on the website at www.companieshouse.gov.uk or email enquiries@companieshouse.gov.uk

This form is available in an alternative format. Please visit the forms page on the website at www.companieshouse.gov.uk



FILE COPY

CERTIFICATE OF THE REGISTRATION OF A CHARGE

Company number: 8705972

Charge code: 0870 5972 0001

The Registrar of Companies for England and Wales hereby certifies that a charge dated 25th June 2015 and created by PRO BONO BIO PLC was delivered pursuant to Chapter A1 Part 25 of the Companies Act 2006 on 7th July 2015

Given at Companies House, Cardiff on 14th July 2015

(P)



Companies House




THE OFFICIAL SEAL OF THE
REGISTRAR OF COMPANIES

Dated 25 JUNE 2015

- (1) **PRO BONO BIO PLC** and others as Chargors
- (2) **KNIGHT THERAPEUTICS INC.** as Lender

DEBENTURE

We certify that, save for material redacted pursuant to s 859G of the Companies Act 2006, this is a true copy of the part of the charging instrument signed by or on behalf of the chargor, and attaches a true copy of the signature page to each other part of such charging instrument

Signed 
Dentons UKMEA LLP

Date 06-07-2015

MAYER • BROWN

LONDON

CONTENTS

Clause	Page
---------------	-------------

SECTION 1 INTERPRETATION

1	Definitions and interpretation	1
---	--------------------------------------	---

SECTION 2 COVENANT TO PAY; GRANTING AND PERFECTION OF SECURITY

2.	Payment of the Secured Liabilities	6
3	Security	6
4	Crystallisation of floating charge	7
5.	Perfection of security and further assurance	8

SECTION 3 ASSET COVENANTS

6.	Negative pledge and disposals	10
7.	Other Covenants of General Application	10
8.	Covenants for title	10
9	Mortgaged Properties	11
10.	The Investments	11
11.	Intellectual Property	13
12.	Assigned Documents	13

SECTION 4 ENFORCEMENT OF SECURITY

13	Enforcement – general provisions	14
14	Right of Appropriation	15
15.	Appointment of Receiver	15
16.	Appointment of Administrator	19
17.	Application of proceeds	19

SECTION 5 GENERAL SECURITY PROVISIONS

18.	General security provisions	21
19.	Power of attorney	23
20	Release	24
21	Reinstatement	24

CONTENTS

Clause	Page
--------	------

SECTION 6 ADMINISTRATION

22.	Transfers	25
23.	Communications	25
24.	Calculations and certificates	26
25.	Partial invalidity	26
26.	Remedies and waivers.....	26
27.	Amendments and waivers.	26
28.	Counterparts.....	26

SECTION 7 GOVERNING LAW AND ENFORCEMENT

29.	Governing law.....	27
30.	Enforcement	27

Schedules

1.	The Chargors.....	27
2.	Assigned Documents	28
3.	Notice of Assignment of Assigned Document	32
4.	Notice of Assignment of Insurance... ..	35
5.	Notice of Charge.....	37
6.	Intellectual Property	39

THIS DEBENTURE is dated 25 June 2015 and made between.

- (1) THE PERSONS listed in Schedule 1 (*The Chargors*) (each a "Chargor" and together the "Chargors"); and
- (2) KNIGHT THERAPEUTICS INC. (the "Lender").

BACKGROUND:

- (A) By a facility agreement dated on or around the date of this Debenture and made between (1) Pro Bono Bio plc as borrower and (2) Knight Therapeutics Inc as Lender (the "**Facility Agreement**"), the Lender has agreed to provide a term loan to the Borrower on the terms of the Facility Agreement.
- (B) The provision of this Debenture is a condition precedent to the obligations of the Lender under the Facility Agreement.
- (C) This document is the deed of each Chargor, even if it has not been duly executed by the Lender or has been executed by the Lender but not as a deed.

THIS DEBENTURE WITNESSES that:

**SECTION 1
INTERPRETATION**

1 DEFINITIONS AND INTERPRETATION

1.1 Terms defined in the Facility Agreement

Terms defined in the Facility Agreement but not in this Debenture shall have the same meanings in this Debenture as in the Facility Agreement.

1.2 Definitions

In addition, in this Debenture:

"Assigned Documents" means the documents set out in Schedule 2 (Assigned Documents).

"Authorisation" means an authorisation, consent, approval, resolution, licence, exemption, filing, notarisation or registration.

"Borrower" means Pro Bono Bio plc, a company incorporated in England and Wales (registered number 08705972).

"Debts" means any book or other debt, revenue or claim (and the proceeds of any debt, revenue or claim) and the benefit of any Lien, guarantee or other right of any nature in relation to any of them and in relation to a Chargor, **"its Debts"** means all Debts in which it has any rights.

"Discharge Date" has the meaning given to it in Clause 18.1 (*Continuing security*).

"Excluded Shares" means PBB (Malta) Limited's shareholding in Dialog Devices Limited (company registration number 04545195).

"Facility Agreement" has the meaning given to it in Recital (A).

"IA" means the Insolvency Act 1986.

"Insolvency" of a person includes the dissolution, bankruptcy, insolvency, winding-up, liquidation, administration, examination, amalgamation, reconstruction, reorganisation, arrangement, adjustment, administrative or other receivership or dissolution of that person, the official management of all of its revenues or other assets or the seeking of protection or relief of debtors and any equivalent or analogous proceeding by whatever name known and in whatever jurisdiction.

"Instrument" means any document (which term includes any form of writing) under which any obligation is evidenced or undertaken or any Lien (or right in any Lien) is granted or perfected or purported to be granted or perfected

"Insurance" means any policy or contract of insurance (excluding third party liability insurance) and including, for the avoidance of doubt, any renewal of or replacement for any policy or contract of insurance and in relation to a Chargor **"its Insurances"** means all Insurances in which it has any rights (including as loss payee or additional insured).

"Insurance Proceeds" means any monies which may from time to time be payable to or received by any Chargor (whether as an insured party, beneficiary or as loss payee) under any Insurance and the proceeds of all claims made by any Chargor under any Insurance.

"Intellectual Property" means all intellectual property, including patents, utility models, trade and service marks, trade names, domain names, right in designs, copyrights, moral rights, topography rights, rights in databases, trade secrets and know-how, in all cases whether or not registered or registrable and including registrations and applications for registration of any of these and rights to apply for the same and all rights and forms of protection of a similar nature or having equivalent or similar effect to any of these anywhere in the world (including the trade marks, patents, patent applications and rights listed in Schedule 5) and, in relation to a Chargor, **"its Intellectual Property"** means all Intellectual Property in which it has any rights (including any listed in Schedule 5)

"Investment" means any share, stock, debenture, bond or other security or investment (in each case together with any associated dividends, allotments, offers, rights and benefits, interests and other assets) (but specifically excluding the Excluded Shares) and, in relation to a Chargor, **"its Investments"** means all Investments in which it has any rights and all its rights against any nominee or other trustee, fiduciary, custodian or clearing system with respect to any Investments (other than, in the case of PBB (Malta) Limited only, the Excluded Shares).

"Lease" means any lease, tenancy, licence, sub-lease, sub-licence or other occupational right

"LPA" means the Law of Property Act 1925.

"Mortgaged Properties" has the meaning given to it in Clause 3 1(a) (*Land*), "Mortgaged Property" means any of them and any reference to one or more of the Mortgaged Properties includes all or any part of it or each of them.

"Notice of Assignment" means a notice of assignment substantially in the form set out in Schedule 3 (*Notice of Assignment of Assigned Document*), as appropriate, or in such other form as may be specified by the Lender

"Notice of Charge" means a notice of charge substantially in the form set out in Schedule 6 (*Notice of Charge*) or in such other form as may be specified by the Lender.

"Party" means a party to this Debenture.

"Planning Acts" means the Town and Country Planning Act 1990, the Planning (Listed Buildings and Conservation Areas) Act 1990, the Planning (Hazardous Substances) Act 1990, the Planning (Consequential Provisions) Act 1990 and the Planning and Compensation Act 1991, together with all other statutes from time to time governing or controlling the use or development of land.

"Receiver" means any receiver, receiver and manager or administrative receiver appointed under this Debenture by the Lender over all or any of the Secured Assets whether solely, jointly, severally or jointly and severally with any other person and includes any substitute for any of them appointed from time to time.

"Secured Assets" means the assets from time to time the subject of this Security, "Secured Asset" means any of them and any reference to one or more of the Secured Assets includes all or any part of it or each of them.

"Secured Liabilities" means all monies from time to time due or owing, and all obligations and other actual or contingent liabilities from time to time incurred, by the Borrower to the Lender under the Loan Documents

- (a) in whatever currency; and
- (b) whether due, owing or incurred alone or jointly with others or as principal, surety or otherwise,

but excluding any money, obligation or liability which would cause the covenant set out in Clause 2 1 (*Covenant to pay*) or the security which would otherwise be constituted by this Debenture to be unlawful or prohibited by any applicable law or regulation.

"Security Documents" means this Debenture and any other document guaranteeing or creating security for or supporting the obligations of any Chargor to the Lender in connection with the Facility Agreement.

1.3 Construction

- (a) In this Debenture, any reference to

- (i) **"assets"** includes present and future properties, revenues, rights and other assets of every description (and any reference to a particular type or category of assets includes any present or future assets of that type or category);
- (ii) the **"Chargors"** includes a reference to any one or more of them as well as a reference to all of them;
- (iii) **this Debenture** includes the Recitals and Schedules which form part of this Debenture for all purposes;
- (iv) a **"disposal"** includes any lease, licence, transfer, sale or other disposal of any kind (with related words being construed accordingly);
- (v) any **Loan Document**, other **Instrument** or other **document** is to that Loan Document, other Instrument or other document as supplemented, otherwise amended, replaced or novated from time to time (however fundamental that amendment, novation or replacement may be, even if it involves increased, new, additional and/or replacement facilities or an increase in any other amount or rate);
- (vi) the masculine, feminine or neuter **gender** respectively includes the other genders and the **singular** includes the plural (and vice versa);
- (vii) **"including"** means "including without limitation" (with related words being construed accordingly), **"in particular"** means "in particular but without limitation" and other **general words** shall not be given a restrictive interpretation by reason of their being preceded or followed by words indicating a particular class of assets, matters or things;
- (viii) **"indebtedness"** includes any obligation (whether incurred as principal or as surety) for the payment or repayment of money, whether present or future, actual or contingent;
- (ix) a **"person"** includes any individual, firm, company or other corporation, government, state or agency of a state or any association, trust or partnership (whether or not having separate legal personality) or two or more of them and any reference to a **Party** or other **particular person** includes its successors in title, permitted assignees and permitted transferees in accordance with their respective interests;
- (x) a **provision of law** is to that provision as amended, re-enacted or replaced from time to time and includes any subordinated legislation in force under it from time to time;
- (xi) a **"Recital"** is to a statement made under the heading "Background" above, any reference to a **"Clause"** or to a **"Schedule"** is to a clause of or a schedule to this Debenture (as the case may be),
- (xii) **"regulation"** includes any regulation, rule, official directive, notice, request, code of practice, guideline, demand or decision (in each case

whether or not having the force of law) of any governmental, intergovernmental or supranational body, agency, department or regulatory, self-regulatory or other authority or organisation;

- (xiii) a **"right"** includes any title, estate, interest, claim, remedy, power, authority, discretion or other right of any kind, both present and future (and any reference to rights in a particular asset or type or category of assets includes any rights in the proceeds of any disposal of that asset or any assets within that type or category),
- (xiv) **"tax"** means any tax, levy, impost, duty or other charge or withholding of a similar nature (including any penalty or interest payable in connection with any failure to pay or any delay in paying any of the same); and
- (xv) **"this Security"** means the Liens constituted by or pursuant to this Debenture.

- (b) The index and Clause, and Schedule headings are for ease of reference only.
- (c) If there is any inconsistency between the terms of this Debenture and those of the Facility Agreement, the terms of the Facility Agreement shall prevail.
- (d) The liabilities of the Chargors under this Debenture are joint and several.

1.4 Third party rights

A person who is not a Party has no right under the Contracts (Rights of Third Parties) Act 1999 to enforce or enjoy the benefit of any term of this Debenture.

SECTION 2
COVENANT TO PAY; GRANTING AND PERFECTION OF SECURITY

2. PAYMENT OF THE SECURED LIABILITIES

2 1 Covenant to pay

Each Chargor covenants with the Lender that it shall pay and discharge, or procure the payment or discharge of, each of the Secured Liabilities payable by it when due and payable.

3. SECURITY

3 1 Fixed charges

Subject to Clause 5.4 (*Non-Assignable Rights*), as continuing security for the payment and discharge of the Secured Liabilities, each Chargor with full title guarantee charges to the Lender by way of first fixed charge (which so far as it relates to land in England and Wales vested in any Chargor as at the date of this Debenture will be a charge by way of first legal mortgage and so far as it relates to other land shall take effect as an equitable mortgage).

- (a) **Land:** all of its rights as at the date of this Debenture in all of its rights in any land (together the "**Mortgaged Properties**") in each case together with all of its rights in all buildings, structures, erections, fixtures and fittings (including trade fixtures and fittings) from time to time on any of the Mortgaged Properties and any proceeds of disposal of any of the Mortgaged Properties;
- (b) **Chattels:** all of its rights in any plant, machinery, vehicles, equipment and other chattels (but excluding its stock in trade or work in progress),
- (c) **Goodwill:** any goodwill and uncalled capital from time to time and all of its rights to future calls in respect of capital;
- (d) **Bank accounts:** all of its rights in any credit balances on any bank accounts and the indebtedness represented by them;
- (e) **Other Debts:** all of its rights in its Debts;
- (f) **Shares and other Investments:** all of its rights in its Investments including in any uncalled capital;
- (g) **Intellectual property rights:** all of its rights in its Intellectual Property; and
- (h) **Licences:** all licences, consents and other Authorisations held in connection with its business or the use of any Secured Assets and all of its rights in connection with them.

3.2 Assignments

Subject to Clause 5.4 (*Non-Assignable Rights*), as security for the payment and discharge of the Secured Liabilities, each Chargor with full title guarantee assigns absolutely to the Lender

- (a) **Insurance:** all of its rights in its Insurances, including those relating to the Mortgaged Properties, and in any Insurance Proceeds; and
- (b) **Assigned Documents:** all of its rights under the Assigned Documents.

For the avoidance of doubt, each Chargor will remain at all times liable in respect of all of its obligations under each of the Assigned Documents to the same extent as if this Security had not been created and neither the Lender nor any Receiver will be under any obligation or liability to any Chargor or to any other person under or in respect of any Assigned Document.

3.3 Floating charge

As security for the payment and discharge of the Secured Liabilities, each Chargor with full title guarantee charges to the Lender by way of first floating charge the whole of its undertaking and other assets (other than assets validly and effectively charged or assigned (whether at law or in equity) from time to time pursuant to Clauses 3.1 and 3.2 by way of fixed security and, in the case of PBB (Malta) Limited only, other than the Excluded Shares). Schedule B1, Paragraph 14 IA shall apply to the floating charge contained in this Debenture.

3.4 Trust

If or to the extent that the assignment or charging of any Secured Asset is ineffective because of a prohibition on that assignment or charging, the Chargor holds it on trust for the Lender to the extent doing so would not breach any provision or term contained in the relevant Secured Asset.

4. CRYSTALLISATION OF FLOATING CHARGE

4.1 Crystallisation by notice

The Lender may at any time by notice in writing to a Chargor convert the floating charge created by that Chargor in Clause 3.3 (*Floating charge*) into a fixed charge with immediate effect as regards any Secured Asset specified in the notice if:

- (a) an Event of Default has occurred and is continuing; or
- (b) the Lender considers (acting reasonably) that any Secured Asset is in danger of being seized or sold pursuant to any form of legal process or otherwise in jeopardy.

4.2 Automatic crystallisation

The floating charge created by a Chargor in Clause 3.3 (*Floating charge*) shall automatically (without notice to that Chargor) be converted into a fixed charge with immediate effect as regards all assets subject to the floating charge if:

- (a) that Chargor creates a Lien other than a Permitted Lien over any Secured Asset or attempts to do so or any Secured Asset is disposed of contrary to Clause 6.2 (*No disposals*) or is otherwise in jeopardy;
- (b) any person levies or attempts to levy any distress, execution, sequestration or other process against any Secured Asset;
- (c) the Lender receives notice of a proposal or intention to wind up, or appoint an administrator of, that Chargor or if that Chargor is wound up or has an administrator appointed, or
- (d) on the crystallisation of any other floating charge over the Secured Assets

Nothing in this Clause 4 shall affect the crystallisation of the floating charge created by any Chargor under applicable law and regulation

5. PERFECTION OF SECURITY AND FURTHER ASSURANCE

5.1 Notice of Assignment

Each Chargor shall promptly upon a request from the Lender during the continuance of an Event of Default:

- (a) deliver (with a copy to the Lender) a Notice of Assignment, duly completed, to any other party to an Assigned Document specified by the Lender;
- (b) deliver (with a copy to the Lender) a Notice of Assignment, duly completed, to any insurer liable on the Insurance of any Chargor agreed between the relevant Chargor and the Lender, and
- (c) use its reasonable endeavours to procure that each addressee of a Notice of Assignment acknowledges that Notice of Assignment in the form attached to that Notice of Assignment (or in such other form as the Lender may approve (acting reasonably)),

and the Lender shall not deliver a Notice of Assignment on any Chargor's behalf unless done pursuant to Clause 19 (*Power of attorney*) following the occurrence of an Event of Default which is continuing.

5.2 Notice of Charge

Each Chargor shall promptly upon a request from the Lender during the continuance of an Event of Default deliver (with a copy to the Lender) a Notice of Charge, duly completed, to any bank specified by the Lender, being a bank with which any of its bank accounts are opened or maintained, and the Lender shall not deliver a Notice of

Charge on any Chargor's behalf unless done pursuant to Clause 19 (*Power of attorney*) following the occurrence of an Event of Default which is continuing.

5.3 Further assurance

Each Chargor shall take or cause to be taken such action and execute and deliver or cause to be executed and delivered to the Lender such agreements, documents and instruments as the Lender shall request, and register, file or record the same (or a notice or financing statement in respect thereof) in all offices where such action, execution, delivery, registration, filing or recording is, in the opinion of the Lender or Lender's counsel, necessary or advisable to constitute, perfect and maintain the Security Documents as first-ranking Liens of the Credit Party granting such Liens, subject only to the Permitted Liens, in all jurisdictions reasonably required by the Lender, in each case within a reasonable time after the request therefor by the Lender or Lender's counsel, and in each case in form and substance satisfactory to the Lender and Lender's counsel, acting reasonably

5.4 Non-Assignable Rights

If the rights of a Chargor under a document or to any other asset cannot be secured in the manner contemplated by this Debenture without the consent of a party to that document, or a Chargor purports to charge or assign an asset under this Debenture and such charge or assignment breaches a term of any agreement binding on such party in respect of that asset because the consent of a person has not been obtained:

- (a) subject to (c) below, the security created pursuant to this Debenture will secure all amounts which such party may receive, or has received, under that document or other asset but exclude the document or other asset itself, and the relevant charge or assignment will (to the extent no breach of the relevant agreement would occur) secure the rights in respect of that document or other asset but shall exclude the asset itself;
- (b) unless the Lender otherwise requires, the relevant Chargor must use reasonable endeavours to obtain the consent of the relevant party and once obtained, shall, as soon as reasonably practicable, provide a copy of such consent to the Lender; and
- (c) upon receipt of the relevant consent, the relevant document and/or other asset shall become subject to this Debenture in favour of the Lender under the relevant provision of Clause 3 (*Security*).

5.5 Confidentiality

Subject to Clause 22.3 (*Disclosure of information*), the Lender agrees that the terms of this Debenture and this Security are confidential as between the parties and undertakes that it shall not (i) give any notice in respect of or otherwise disclose the same to any person unless an Event of Default has occurred and is continuing, or (ii) make any declaration, registration, filing or similar with respect to this Debenture of this Security unless necessary to ensure the legality, validity, enforceability or admissibility in evidence in England or Malta of same

SECTION 3 ASSET COVENANTS

6 NEGATIVE PLEDGE AND DISPOSALS

6.1 Negative pledge

The Borrower will not create, incur, assume or permit to exist any Lien upon any of its Secured Assets except a Permitted Lien.

6.2 No disposals

The Borrower will not, except for Permitted Dispositions, dispose of, in one transaction or a series of transactions, all or any part of its Secured Assets, whether now owned or hereafter acquired.

7. OTHER COVENANTS OF GENERAL APPLICATION

7.1 Application of insurance proceeds

Clause 17.2 (*Insurance proceeds*) provides for the application of any insurance proceeds.

8. COVENANTS FOR TITLE

The obligations of each Chargor under this Debenture shall be in addition to the covenants for title deemed to be included in this Debenture by virtue of Part 1 Law of Property (Miscellaneous Provisions) Act 1994.

8.1 Bank accounts

Until the Lender has given notice to a Chargor to the contrary whilst an Event of Default is continuing, each Chargor shall be entitled to continue to exercise all of its rights in any credit balances on any bank accounts and the indebtedness represented by them, including (without limitation) the right to withdraw amounts from any bank account.

8.2 Preservation of the Security Assets

Each Chargor shall:

- (a) keep all land, all Equipment and all other tangible assets which form part of the Security Assets in good and substantial repair, fair wear and tear excepted;
- (b) pay all tax, rents, rates, duties, fees, charges, assessments, impositions, calls, instalments and outgoings which are properly payable at any time until the Discharge Date in respect of any Secured Asset or by the owner or occupier of it (and if it fails to pay that amount when due, the Lender may pay it),

9 MORTGAGED PROPERTIES

9.1 Delivery of Mortgaged Property title documents

- (a) Each Chargor shall, on the date of this Debenture and from time to time, deliver (or procure that there are delivered) to the Lender (or a nominee specified by the Lender acting on its behalf) all title documents (including all local land charges, Land Registry search certificates and planning and other statutory consents) relating to the Mortgaged Properties. The Lender shall be entitled to hold or retain (or have its nominee hold or retain) them.
- (b) On completion of the registration of this Debenture against any Land Registry title comprised in the Mortgaged Properties, the Chargors shall supply the Lender with a copy of the title information document for that title.

9.2 Future acquisitions

Each Chargor shall, at all times until the Discharge Date, notify the Lender promptly of any conveyance, transfer or other disposition for or effecting the acquisition by it or any nominee on its behalf of any land.

9.3 Local authority proposals

- (a) The Chargors shall:
 - (i) give to the Lender a copy of any notice or order (or any proposal for a notice or order) given, issued or made by any local or other authority relating to any of the Mortgaged Property; and
 - (ii) take all necessary steps to comply with that notice, order or proposal;
- (b) Any compensation received as a result of a notice, order or proposal referred to in Clause 9.3(a), pursuant to s25 Law of Property Act 1969 and/or the Landlord and Tenant Act 1954 or otherwise, shall be held on trust for, and promptly paid to, the Lender. The Lender shall apply the compensation as if it constituted proceeds of an enforcement of this Debenture.

9.4 Subsequent incumbrancer

For the purposes of ss99 and 100 LPA, "mortgagor" shall include any incumbrancer (as defined in the LPA) deriving title from a Chargor and s99(18) and s100(12) LPA shall not apply.

10 THE INVESTMENTS

10.1 Delivery of Investment title documents; registration

- (a) Unless otherwise agreed in writing by the Lender, each Chargor shall deliver (or procure that there are delivered) to the Lender (or a nominee specified by the Lender acting on its behalf) all share certificates or other documents of title to or representing its Investments, together with (in each case in form and substance satisfactory to the Lender (acting reasonably)):

- (i) any instrument of transfer or assignment of such Investments specified by the Lender duly executed by each person in whose name any of those Investments are registered or held (with the name of the transferee or assignee, the consideration and the date left blank); and
 - (ii) any other Instrument, other document or thing which is necessary to perfect its security over that Chargor's Investments, including waivers of pre-emption and other rights which may affect the exercise of any rights under, or the enforcement of, this Debenture.
- (b) The Lender shall be entitled to hold or retain (or have its nominee hold or retain) all items delivered pursuant to Clause 10.1(a).
 - (c) During the continuance of an Event of Default the Lender may at any time have any of the Investments registered in its name or in the name of a nominee specified by it acting on its behalf.

10.2 Rights before an Event of Default

Before the occurrence of an Event of Default:

- (a) Each Chargor shall be entitled to:
 - (i) hold all dividends, interest and other monies paid on and received by it in respect of its Investments, and
 - (ii) exercise all voting and other rights attached to its Investments; and
- (b) no Chargor shall.
 - (i) exercise any rights attached to the Investments in any manner which is, or could reasonably be expected to be, materially prejudicial to this Security; and
 - (ii) without the prior written consent of the Lender, permit or agree to any variation of the rights attaching to the Investments, participate in any rights issue, elect to receive or vote in favour of receiving any dividend other than in the form of cash or participate in any resolution concerning a winding-up, liquidation or administration where (in each case) to do so would be materially prejudicial to the interests of the Lender under the Loan Documents.

10.3 Rights after an Event of Default

During the continuance of an Event of Default, the Lender (or its nominee) may at the Lender's discretion (and in the name of the relevant Chargor or otherwise) exercise all voting and other rights attached to the Investments and all rights to receive dividends, interest and other monies paid on or to be received in respect of the Investments without any further consent or authority on the part of any Chargor

11 INTELLECTUAL PROPERTY

At all times until the Discharge Date each Chargor shall do all acts and things which may be necessary to preserve and maintain the subsistence and validity of its Intellectual Property where failure to do such act or thing would have a Material Adverse Effect.

12 ASSIGNED DOCUMENTS

Each Chargor shall:

- (a) not repudiate, rescind or otherwise terminate or permit to be terminated any Assigned Document where such repudiation, rescission or termination would have a Material Adverse Effect without the prior written consent of the Lender; and
- (b) use commercially reasonable efforts to pursue any remedies available to it for any breach of, or in respect of any claim in relation to, any Assigned Document where failure to pursue would have a Material Adverse Effect.

SECTION 4
ENFORCEMENT OF SECURITY

13. ENFORCEMENT – GENERAL PROVISIONS

13.1 Enforcement

- (a) On or at any time after the occurrence of an Event of Default and whilst it is continuing:
 - (i) this Security shall become immediately enforceable and the Lender may enforce all or any of its rights under this Debenture as it thinks fit. In particular, it may without further notice exercise in relation to the Secured Assets:
 - (A) the power of sale and all other powers conferred on mortgagees by the LPA (or otherwise by law) or on an administrative receiver by the IA, in either case as extended or otherwise amended by this Debenture; and
 - (B) (without first appointing a Receiver) any or all of the rights which are conferred by this Debenture (whether expressly or by implication) on a Receiver.
- (b) The Security created by this Debenture shall become enforceable if the Chargor so requests.

13.2 LPA provisions

- (a) The Secured Liabilities shall be deemed for the purposes of all powers implied by statute to have become due and payable within the meaning of s101 LPA immediately on the execution of this Debenture.
- (b) s93(1) LPA (restriction on the consolidation of mortgages), s103 LPA (restricting the power of sale) and s109 LPA (restricting the power to appoint a receiver) shall not apply to this Security.

13.3 Protection of third parties

- (a) No purchaser, mortgagee or other person dealing with a Receiver or the Lender shall be bound to enquire whether its right to exercise any of its rights has arisen or become exercisable, or be concerned as to the application of any money paid, raised or borrowed or as to the propriety or regularity of any sale by or other dealing with that Receiver or the Lender.
- (b) All of the protection to purchasers contained in ss104 and 107 LPA and s42(3) IA shall apply to any person purchasing from or dealing with a Receiver or the Lender as if the Secured Liabilities had become due and the statutory powers of sale and of appointing a Receiver in relation to the Secured Assets had arisen on the date of this Debenture.

13.4 Delegation

The Lender may delegate to any person or persons all or any of the rights which are exercisable by it under this Debenture. A delegation under this Clause may be made in any manner (including by power of attorney) and on any terms (including power to sub-delegate) which the Lender may think fit.

13.5 No liability

None of the Lender, any Receiver or any Administrator shall be liable as a mortgagee in possession or otherwise to account in relation to all or any part of the Secured Assets for any loss on realisation or for any other action, default or omission for which it, he or she might be liable unless caused by its or its delegates or sub-delegates negligence or wilful misconduct

13.6 Enforcement costs

The Chargors shall, within three Business Days of demand, pay to the Lender or any Receiver the amount of all costs and expenses (including legal fees) incurred by the Lender or any Receiver in connection with the enforcement of, or the preservation of any rights under, this Debenture.

14. RIGHT OF APPROPRIATION

14.1 Application of right of appropriation

This Clause 14 applies to the extent the Secured Assets constitute "financial collateral" and this Debenture constitutes a "financial collateral arrangement" (within the meaning of the Financial Collateral Arrangements (No. 2) Regulations 2003).

14.2 Exercise of right of appropriation

If and to the extent that this Clause 14 applies, the Lender may appropriate the Secured Assets. If the Lender exercises its right of appropriation then it shall for these purposes value:

- (a) any relevant Specified Account or other bank account and the amount standing to the credit of that account, together with any accrued interest not credited to the account, at the time of the appropriation; and
- (b) any other relevant Secured Asset by reference to an independent valuation or other procedure determined by the Lender, acting reasonably, at the time of the appropriation.

15. APPOINTMENT OF RECEIVER

15.1 Appointment of Receiver

Without prejudice to any statutory or other powers of appointment of the Lender under the LPA as extended by this Debenture or otherwise, at any time after this Security has become enforceable or if the relevant Chargor so requests in writing at

any time the Lender may without further notice to any Chargor do any of the following.

- (a) appoint by deed or otherwise (acting through a duly authorised officer) any one or more persons qualified to act as a Receiver to be a Receiver of all or any part of the Secured Assets;
- (b) either at the time of appointment or any time after that appointment fix his or their remuneration (without being limited by the maximum rate specified in s109(6) LPA); and
- (c) (except as otherwise required by statute) remove any Receiver and appoint another or others in his or her place.

15.2 Powers of Receiver

Every Receiver shall have in relation to the Secured Assets (every reference in this Clause 15.2 to "Secured Assets" being a reference only to all or any part of the Secured Assets in respect of which that Receiver was appointed) the powers granted by the LPA to any receiver appointed under it or to any mortgagor or mortgagee in possession and (whether or not the Receiver is an administrative receiver) the powers granted by the LA to any administrative receiver, all as varied and extended by this Debenture. In addition, but without limiting the preceding sentence, every Receiver shall have power to do the following:

- (a) **Collection:** enter on, take possession of, collect and get in the Secured Assets whether accrued before or after the date of his or her appointment and for those purposes make any demands and take any actions or other proceedings which may seem to him or her expedient;
- (b) **Compliance with Deed:** comply with and perform all or any of the acts, matters, omissions or things undertaken to be done or omitted by the relevant Chargor under this Debenture;
- (c) **Dealing with Secured Assets:** sell or otherwise dispose of the Secured Assets grant Leases, easements, rights or options over or in respect of them and surrender, accept the surrender or vary any Lease, agreement or arrangement relating to them. This power may be exercised without the need to comply with ss99 and 100 LPA. Any disposal or other dealing under this Clause 15.2(c) may be effected in the manner and on any terms which the Receiver thinks fit, for consideration consisting of cash, debentures or other obligations, shares or other valuable consideration and this consideration may be payable in a lump sum or by instalments spread over such period as the Receiver may think fit;
- (d) **Severance of assets:** sever from the premises to which they are annexed and sell separately (in accordance with Clause 15.2(c)) any plant, machinery or fixtures;
- (e) **Upkeep of Secured Assets:** repair, decorate, furnish, maintain, alter, improve, replace, renew or add to the Secured Assets as the Receiver shall think fit and

effect, maintain, renew or increase indemnity insurance and other insurances and obtain bonds,

- (f) **Dealing with third parties:** appoint or dismiss officers, employees, contractors or other agents and employ professional advisers and others on such terms (as to remuneration and otherwise) as the Receiver may think fit;
- (g) **Agreements:** perform, repudiate, terminate, amend or enter into any arrangement or compromise any contracts or agreements which the Receiver may consider expedient;
- (h) **Proceedings:** settle, arrange, compromise or submit to arbitration any accounts, claims, questions or disputes which may arise in connection with the business of the relevant Chargor or the Secured Assets and bring, prosecute, defend, enforce, compromise, submit to and discontinue any actions, suits, arbitrations or other proceedings;;
- (i) **Rights in connection with Secured Assets:** exercise or permit the relevant Chargor or any nominee of the relevant Chargor to exercise any rights incidental to the ownership of the Secured Assets in such manner as the Receiver may think fit;
- (j) **Assets and rights:** purchase, lease, hire or otherwise acquire any assets or rights of any description which the Receiver shall consider necessary or desirable for the carrying on, improvement or realisation of the Secured Assets or the business of the relevant Chargor or otherwise for the benefit of the Secured Assets;
- (k) **Landlord and tenant powers:** exercise any rights conferred on a landlord or a tenant by any applicable law or regulation in relation to the Secured Assets;
- (l) **Receipts and discharges:** give valid receipts for all monies and execute all discharges, assurances and other documents which may be proper or desirable for realising the Secured Assets and redeem, discharge or compromise any Lien whether or not having priority to this Security or any part of it,
- (m) **All other acts:** execute and do all such other acts, things and documents as the Receiver may consider necessary for the realisation or preservation of the Secured Assets or incidental or conducive to any of the rights conferred on or vested in him or her under or by virtue of this Debenture or otherwise and exercise and do in relation to the Secured Assets, and at the cost of the relevant Chargor, all the rights and things which he or she would be capable of exercising or doing if he or she were the absolute beneficial owner of the same; and
- (n) **Name of Chargor:** use the name of the relevant Chargor or his or her own name to exercise all or any of the rights conferred by this Debenture.

15.3 Agent of the relevant Chargor

Any Receiver appointed under this Debenture whether acting solely or jointly shall be deemed to be the agent of the relevant Chargor and to be in the same position as a receiver appointed under the LPA and the relevant Chargor shall be solely responsible for his or her acts, omissions, defaults, losses and misconduct and for his or her remuneration and the Lender shall not be in any way liable or responsible either to the relevant Chargor or to any other person for any Receiver

15.4 Joint appointment

If at any time two or more persons have been appointed as Receivers of the same Secured Assets, each one of those Receivers shall be entitled to exercise individually all of the rights conferred on Receivers under this Debenture to the exclusion of the other or others in relation to any of the Secured Assets in respect of which he or she has been appointed unless the Lender shall state otherwise in the document appointing him or her.

15.5 Receiver's remuneration

Every Receiver shall be entitled to remuneration for his services at a rate to be fixed by agreement between him and the Lender, and the maximum rate specified in section 109(6) of the Act shall not apply

15.6 General indemnity

Pro Bono Bio plc agrees to indemnify and hold harmless the Lender and each of its Affiliates, and Subsidiaries, and its respective officers, directors, employees and agents, and any Receiver (each an "Indemnified Party") from and against any and all obligations, losses, damages, penalties, actions, judgments, suits, claims, costs, expenses and disbursements of any kind or nature (including, without limitation, the disbursements and the fees (on a solicitor-client basis) of one legal counsel (unless it would be inappropriate for one counsel to represent all Indemnified Parties due to a conflict of interest or otherwise in which case, all legal counsel for each Indemnified Party) in connection with any investigative, administrative or judicial proceedings, whether or not any Indemnified Party shall be designated a party thereto), (collectively, "Losses") which may be imposed on, incurred by, or asserted against, any Indemnified Party (whether direct, indirect or consequential and whether based on any federal, provincial, state or local laws or regulations, including, without limitation, securities, environmental and commercial laws and regulations, under common law or in equity, or based on contract or otherwise) in any manner relating to or arising out of this Debenture, or any act, event or transaction related or attendant thereto, the making and/or the management of the Loan or the use or intended use of the proceeds of the Loan; provided, however that the Borrower shall have no obligation hereunder to any Indemnified Party to the extent that such Losses were caused by or resulted from the wilful misconduct or gross negligence of such Indemnified Party To the extent that the undertaking to indemnify set forth in the preceding sentence may be unenforceable against the Borrower because it violates any law or public policy, the Borrower shall satisfy such undertaking to the maximum extent permitted by Applicable Law. Any Losses covered by this indemnity shall be paid to each Indemnified Party on demand, and, failing prompt payment, shall,

together with interest thereon at the Deemed Interest Rate from the date incurred by each Indemnified Party until paid in full, be added to the Obligations and be secured by the Collateral. The provisions of this Section 15.6 shall survive the satisfaction and payment of all Obligations and the termination of this Debenture.

16 APPOINTMENT OF ADMINISTRATOR

16.1 Appointment of Administrator

- (a) The Lender may without notice appoint any one or more persons to be an administrator of any Chargor pursuant to Schedule B1, Paragraph 14 IA at any time after this Security has become enforceable.
- (b) Clause 16.1(a) shall not apply to any Chargor if Schedule B1, Paragraph 14 IA does not permit an administrator of that Chargor to be appointed.
- (c) Any appointment under Clause 16.1(a) shall be in writing signed by a duly authorised officer of the Lender.

16.2 Replacement of an Administrator

The Lender may (subject to any necessary approval from the court) end the appointment of any Administrator by notice in writing signed by a duly authorised officer and appoint under Clause 16.1 a replacement for any Administrator whose appointment ends for any reason.

17. APPLICATION OF PROCEEDS

17.1 Order of priority

Any monies received by the Lender or any Receiver under this Debenture or under the rights conferred by this Debenture shall, after the occurrence of an Event of Default and payment of any claims having priority to this Security, be applied in the following order, but without prejudice to the right of the Lender to recover any shortfall from the Chargors.

- (a) where applicable, in payment of the Receiver's remuneration at such rate as may be agreed with the Lender;
- (b) in or towards discharge of the Secured Liabilities;
- (c) in payment of the surplus (if any) to the person or persons entitled to it.

17.2 Insurance proceeds

- (a) All monies received by any Chargor by virtue of any Insurance on the Secured Assets, whether or not effected under this Debenture:
 - (i) shall be deemed part of the Secured Assets, and
 - (ii) (subject to any rights of third parties arising under any applicable law and regulation relating to the application of insurance monies or under

any Lease under which any Mortgaged Property is demised or let to or by that Chargor) shall be for the account of the relevant Chargor.

- (b) Any monies so paid to the Lender or otherwise received by the Lender by virtue of any insurance on the Secured Assets shall whilst an Event of Default is continuing be applied at the discretion of the Lender either in reduction of the Secured Liabilities or in or towards making good the loss or damage in respect of which they became payable. The Chargors waive any right they may have to require that those monies be applied in or towards making good the loss or damage in respect of which they became payable.
- (c) Whilst no Event of Default is continuing any monies received by the Lender by virtue of any Insurance on the Secured Assets shall be paid to the relevant Chargor as soon as reasonably practicable following receipt.

SECTION 5
GENERAL SECURITY PROVISIONS

18. GENERAL SECURITY PROVISIONS

18.1 Continuing security

This Debenture is a continuing security and regardless of any intermediate payment or discharge in whole or in part to the Lender, shall be binding until the date (the "Discharge Date") on which:

- (a) all of the Secured Liabilities have been unconditionally and irrevocably paid or discharged in full; and
- (b) the Lender has ceased to have any commitment, obligation or other liability (whether actual or contingent) to make any credit or provide any other accommodation to the Borrower under any Loan Document.

18.2 Additional security

This Debenture is in addition to and is not in any way prejudiced by any other guarantee or Lien now or subsequently held by or on behalf of the Lender.

18.3 Waiver of defences

The obligations of each Chargor under this Debenture will not be discharged, impaired or otherwise affected by any act, omission, matter or thing which, but for this Clause 18.3, would reduce, release or prejudice any of its obligations under this Debenture, including (whether or not known to it or the Lender):

- (a) any time, waiver, consent or other indulgence granted to, or composition with, any Chargor or any other person,
- (b) the release of any other Chargor or any other person under the terms of any composition or arrangement with any creditor;
- (c) the taking, variation, compromise, exchange, renewal or release of, or refusal or neglect to perfect, take up or enforce, any rights against, or Lien over the assets of, any Chargor or any other person or any non-presentation or non-observance of any formality or other requirement in respect of any Instrument or any failure to take, or failure to realise the full value of, any Lien;
- (d) any incapacity or lack of power, authority or legal personality of or Insolvency or change in the members or status of any Chargor or any other person; or
- (e) any amendment (however fundamental), replacement, variation, novation, assignment or the avoidance or termination of a Loan Document or any other document or Lien;
- (f) any insolvency, liquidation, administration or similar procedure, or

- (g) any disclaimer, unenforceability, illegality, invalidity or ineffectiveness of any of the Secured Liabilities or any other obligation of any person under any Transaction Document or any other Instrument or Lien.

18.4 Chargor intent

Without prejudice to the generality of Clause 18.3 (*Waiver of defences*), each Chargor expressly confirms that it intends that the Lien created by this Debenture shall extend from time to time to any (however fundamental) variation, increase, extension or addition of or to any of the Loan Documents and/or any facility or amount made available under any of the Loan Documents for the purposes of or in connection with any of the following:

- (a) acquisitions of any nature;
- (b) increasing working capital;
- (c) enabling investor distributions to be made;
- (d) carrying out restructurings;
- (e) refinancing existing facilities;
- (f) refinancing any other indebtedness;
- (g) making facilities available to new borrowers;
- (h) any other variation or extension of the purposes for which any such facility or amount might be made available from time to time, and
- (i) any fees, costs and/or expenses associated with any of the foregoing.

18.5 Immediate recourse

Each Chargor waives any right it may have of first requiring the Lender to proceed against or enforce any Lien or other rights or claim payment from any other person before claiming from it under this Debenture. This waiver applies irrespective of any applicable law and regulation or any provision of any Loan Document to the contrary

18.6 Discretion in enforcement

Until the Discharge Date, the Lender or any Receiver may:

- (a) refrain from applying or enforcing any other monies, Liens or other rights held or received by it in respect of the Secured Liabilities or apply and enforce them in such manner and order as it sees fit (whether against the Secured Liabilities or otherwise) and no Chargor shall be entitled to the benefit of the same; and
- (b) hold in an interest-bearing suspense account any monies received from any Chargor or on account of the Secured Liabilities

18.7 Subsequent Liens

At any time following:

- (a) the Lender's receipt of notice (either actual or constructive) of any subsequent Lien save for a Permitted Lien affecting the Secured Assets;
- (b) the Insolvency of any Chargor; or
- (c) any disposal of all or any of the Secured Assets in breach of Clause 6.2 (*No disposals*),

the Lender may open a new account or accounts in the name of the relevant Chargor (whether or not it permits any existing account to continue) If the Lender does not open such a new account, it shall nevertheless be treated as if it had done so at the time when the notice was received or was deemed to have been received or, as the case may be, the Insolvency commenced or the assignment or transfer occurred and from that time all payments made by the relevant Chargor to, the Lender or received by the Lender for the account of the relevant Chargor shall be credited or treated as having been credited to the new account and shall not operate to reduce the amount secured by this Debenture at the time when the Lender received or was deemed to have received that notice or, as the case may be, the Insolvency commenced or the assignment or transfer occurred.

19. POWER OF ATTORNEY

19.1 Appointment

Each Chargor irrevocably and by way of security appoints the Lender and any Receiver and every delegate referred to in Clause 13.4 (*Delegation*) and each of them jointly and also severally to be its attorney (with full powers of substitution and delegation) and in its name or otherwise and on its behalf and as its act and deed to execute, deliver and perfect all Instruments and other documents and do any other acts and things which may be required or which the attorney may consider desirable in each such case following the occurrence and during the continuance of an Event of Default which is then continuing:

- (a) to carry out any obligation imposed on that Chargor by this Debenture which such Chargor has failed to carry out;
- (b) to carry into effect any disposal or other dealing by the Lender or any Receiver;
- (c) to convey or transfer any right in land or any other asset;
- (d) to get in the Secured Assets; and
- (e) generally to enable the Lender and any Receiver to exercise the respective rights conferred on them by this Debenture or by applicable law and regulation,

and each Chargor undertakes to ratify and confirm all acts and things done by an attorney in the exercise or purported exercise of its powers and all monies spent by an attorney shall be deemed to be expenses incurred by the Lender under this Debenture.

19.2 Irrevocable power

Each Chargor acknowledges that each power of attorney granted by Clause 19.1 is granted irrevocably and for value as part of this Security to secure a proprietary interest of, and the performance of obligations owed to, the donee within the meaning of s4 Powers of Attorney Act 1971.

20 RELEASE

Notwithstanding the security created pursuant to this Debenture, the Lender acknowledges that, if (and to the extent) that any Secured Asset is disposed of in a manner not prohibited by the Facility Agreement, any Lien constituted over the Secured Asset pursuant to this Debenture shall be deemed released and (to the extent applicable) the Secured Asset shall be deemed reassigned to the relevant Chargor automatically and immediately prior to such disposal.

Notwithstanding the security created pursuant to this Debenture, the Lender acknowledges and agrees that:

- (a) nothing in this Debenture shall prevent the Chargors from making a disposal, payment, dividend or other distribution which is not prohibited under the Facility Agreement, and
- (b) the Lender shall, upon reasonable notice and following a request to do so from the Chargors or Receiver or other insolvency officer appointed in respect of a Secured Asset, act to release the security created pursuant to this Debenture granted by the Chargors in favour of the Lender over any such Secured Asset, such party having confirmed in writing to the Lender that such disposal or disposition, as applicable, is not prohibited under the Facility Agreement (on which confirmation the Lender shall be entitled to rely absolutely), and shall, upon the request of a Chargor, issue a letter of non-crystallisation.

21. REINSTATEMENT

- (a) Any release, settlement, discharge, re-assignment or arrangement (in this Clause 21, a "**release**") made by the Lender on the faith of any assurance, security or payment shall be conditional on that assurance, security or payment not being avoided, reduced, clawed back or ordered to be repaid under any law relating to Insolvency.
- (b) If any avoidance, reduction or clawback occurs or order is made as referred to in Clause 21(a), then the release given by the Lender shall have no effect and shall not prejudice the right of the Lender to enforce this Security in respect of the Secured Liabilities. As between the Chargors and the Lender, this Security shall (notwithstanding the release) be deemed to have remained at all times in effect and held by the Lender as security for the Secured Liabilities.

SECTION 6 ADMINISTRATION

22. TRANSFERS

22.1 Lender

The Lender may assign any or all of its rights and transfer any or all of its obligations under this Debenture in accordance with section 13.5 of the Facility Agreement.

22.2 Chargors

No Chargor may assign any of its rights or transfer any of its rights or obligations under this Debenture.

22.3 Disclosure of information

The Lender may disclose any information about the Chargors which it shall consider appropriate to any Affiliate, any of its professional advisers, any person to whom it is proposing to assign or transfer, or has assigned or transferred, any of its rights and obligations under this Debenture or to any person to whom information may be required to be disclosed by any applicable law and regulation.

23. COMMUNICATIONS

23.1 Communications in writing

Any communication to be made or provided under or in connection with this Debenture (including any notices, waivers, consents or other documents) shall be made or provided in English and in writing and, unless otherwise stated, may be delivered by fax, post or personal delivery.

23.2 Addresses

The address and fax number (and the department or officer, if any, for whose attention the communication is to be made) of each Party for any communication to be made or delivered under or in connection with this Debenture is:

- (a) (subject to Clause 23.2)(b)) in the case of the Chargors, that identified for a Borrower or a Guarantor in section 13.1 of the Facility Agreement and, in the case of the Lender, that identified for the Lender in section 13.1 of the Facility Agreement; or
- (b) may in the alternative in the case of any claim form, judgment or other notice of process on any Chargor be delivered or sent to its agent for service of process named in Clause 30.2 (*Service of process*) or its registered office from time to time.

23.3 Delivery

Any communication to be made or provided by one Party to another under or in connection with this Debenture will be effectively made or provided only when

actually received by such Party and then only if it is expressly marked for the attention of the department or officer specified as part of its address details provided under Clause 23.2.

24. CALCULATIONS AND CERTIFICATES

24.1 Accounts

In any litigation or other proceedings arising out of or in connection with this Debenture, the entries made in the accounts maintained by the Lender are prima facie evidence of the matters to which they relate.

24.2 Certificates or determinations

Any certificate or determination of the Lender as to any matter provided for in this Debenture is, in the absence of manifest error, conclusive evidence of the matters to which it relates.

25. PARTIAL INVALIDITY

If, at any time, any provision of this Debenture is or becomes illegal, invalid or unenforceable in any respect under any law of any jurisdiction, neither the legality, validity or enforceability of the remaining provisions nor the legality, validity or enforceability of that provision under the law of any other jurisdiction will in any way be affected or impaired

26. REMEDIES AND WAIVERS

No failure to exercise, nor any delay in exercising, on the part of the Lender, any remedy or other right under this Debenture shall operate as a waiver, nor shall any single or partial exercise of any remedy or other right prevent any further or other exercise or the exercise of any other right. The remedies and other rights provided in this Debenture are cumulative and not exclusive of any remedies and other rights provided by law

27. AMENDMENTS AND WAIVERS

Any term of this Debenture may be amended or waived only with the written consent of the Lender and the Chargors and any such amendment or waiver will be binding on all Parties.

28. COUNTERPARTS

This Debenture may be executed in any number of counterparts, and this has the same effect as if the signatures (and if applicable, seals) on the counterparts were on a single copy of this Debenture.

SECTION 7
GOVERNING LAW AND ENFORCEMENT

29. GOVERNING LAW

This Debenture is governed by, and shall be construed in accordance with, English law.

30. ENFORCEMENT

30.1 Jurisdiction of English courts

- (a) The courts of England have exclusive jurisdiction to settle any dispute arising out of or in connection with this Debenture (including a dispute regarding the existence, validity or termination of this Debenture) (a "**Dispute**").
- (b) The Parties agree that the courts of England are the most appropriate and convenient courts to settle Disputes and accordingly no Party will argue to the contrary.

30.2 Service of process

- (a) Without prejudice to any other mode of service allowed under any relevant law, each Chargor (other than any Chargor incorporated in England and Wales):
 - (i) irrevocably appoints Pro Bono Bio plc as its agent for service of process in relation to any proceedings before the English courts in connection with this Debenture; and
 - (ii) agrees that a failure by the process agent to notify it of the process will not invalidate the proceedings concerned.
- (b) If the appointment by any Chargor of the person mentioned in Clause 30.2(a)(i) ceases to be effective, it shall immediately appoint another person in England as its agent for service of process in relation to any proceeding before the English courts in connection with this Debenture. If it fails to do so (and that failure continues for a period of not less than 15 Business Days), the Lender shall be entitled to appoint such a person by notice to the relevant Chargor.

EXECUTION:

The parties have shown their acceptance of the terms of this Debenture by executing it, in the case of each Chargor as a deed, at the end of the Schedules

**SCHEDULE 1
THE CHARGORS**

Name	Jurisdiction of incorporation	Registration number	Registered office
Pro Bono Bio Entrepreneur Limited	England	07805302	4 th Floor Reading Bridge House George Street Reading Berkshire RG1 8LS
Pro Bono Bio International Trading Limited	Malta	C54787	Palazzo Pietro Stiges 103 Strait Street Valletta VLT1436 Malta
Sequessome Technology Holdings Limited	Malta	C48458	Palazzo Pietro Stiges 103 Strait Street Valletta VLT1436 Malta
Cantab Biopharmaceuticals Patents Limited	Malta	C57672	Palazzo Pietro Stiges 103 Strait Street Valletta VLT1436 Malta
Pro Bono Bio plc	England	08705972	4 th Floor Reading Bridge House George Street Reading Berkshire RG1 8LS
Pro Bono Bio Group plc	England	07802577	4 th Floor Reading Bridge House George Street Reading Berkshire RG1 8LS
PBB (Malta) Limited	Malta	C62504	Palazzo Pietro Stiges 103 Strait Street Valletta VLT1436 Malta
Leverton Licence Holdings Limited	Malta	C48342	Palazzo Pietro Stiges 103 Strait Street Valletta VLT1436 Malta

SCHEDULE 2
ASSIGNED DOCUMENTS

No.	Parties	Title	Date
1	(1) Loxxes Pharma GmbH (2) Pro Bono Bio International Trading Limited	Local Services Agreement (LSA) for the provision of Logistics Services to Pro Bono Bio International Trading Limited	4 July 2012
2	(1) Unidrug Distribution Group Limited (2) Pro Bono Bio Entrepreneur Limited	Contract for the Provision of Pre-Wholesaling Services	12 October 2011
3	(1) IDEA AG (2) Targeted Delivery Technologies Limited (formerly Trans Dermal Technologies Limited) (2) Sequessome Technology Holdings Limited (in its former name of TDT 064 Limited)	Deed of Variation to licence agreement dated 17 February 2006 between Trans Dermal Technologies Limited (1) and IDEA (2) (as amended)	24 June 2011
4	(1) Targeted Delivery Technologies Limited (2) Leverton Licence Holdings Limited	Sub-Licence Agreement for certain uses of the TDT platform	12 April 2011
5	(1) Sequessome Technology Holdings Limited (2) Pro Bono Bio Entrepreneur Limited (3) Pro Bono Bio International Trading Limited	Trading Licence Agreement for the manufacture and sale of certain products using Sequessome technology	22 September 2014
6	(1) Pemberton Marketing	Healthcare Supply Chain Distribution Services Agreement (Consignment	7 May 2013

	International (2) Pro Bono Bio International Trading Limited	Stock (A))	
7	(1) Pemberton Marketing International (2) Pro Bono Bio International Trading Limited	Healthcare Supply Chain Agreement for the provision of Managed Sales Services	28 May 2013
8	(1) Pro Bono Bio International Trading Limited (2) Alfred Gera and Sons Ltd	Distribution Agreement	18 September 2013
9	(1) Pro Bono Bio International Trading Limited (2) Koç Medikal Tibbi Malz. İnş. Gıda. Kom. Kozm Tk. İş. Ci. Sa. Tı. Lt. Şti	Product Distribution Agreement, relating to Flexiseq	16 September 2013
10	(1) Pro Bono Bio International Trading Limited (2) UAB Vilandra	Standard Master Partner Distribution Agreement, relating to Flexiseq (and any variations), Rossoseq and Exoseq	undated
11	(1) Pro Bono Bio International Trading Limited (2) Milanco Trading Limited	Standard Master Partner Distribution Agreement, relating to Flexiseq (and any variations), Rossoseq and Exoseq	5 January 2015
12	(1) Pro Bono Bio International Trading Limited (2) Green Park Medical Ltd	Master Regional Product Distribution Agreement – SE Asia, relating to Flexiseq (and any variations), Rossoseq and Exoseq	1 December 2014
13	(1) Pro Bono Bio International Trading	Standard Master Partner Distribution Agreement, relating to Flexiseq (and	Undated

	Limited (2) Nice Pak Products Pty Ltd	any variations), Rossoseq and Exoseq	
14	(1) Pro Bono Bio International Trading Limited (2) Abu Dhabi International Medical Services LLC	Standard Master Partner Distribution Agreement, relating to Flexiseq (and any variations), Rossoseq and Exoseq	20 October 2014
15	(1) Pro Bono Bio International Trading Limited (2) Sky Med (pty) Limited	Standard Master Partner Distribution Agreement, relating to Flexiseq (and any variations), Rossoseq and Exoseq	1 December 2013

SCHEDULE 3

NOTICE OF ASSIGNMENT OF ASSIGNED DOCUMENT

[On relevant Chargor's notepaper]

To: *[Name and address of other party]*

[Date]

Dear Sirs

[Name and date of Assigned Document]

We refer to an agreement dated [●] 200[●] between us and you (as amended or novated from time to time, the "Agreement").

We give you notice that by a security agreement (the "Agreement") dated [●] 2015 and entered into by us in favour of Knight Therapeutics Inc. (as Lender, as defined in the Deed), we have assigned all our rights under the Agreement including the right to receive any payments due under the Agreement.

Please note the following:

- (a) we shall at all times remain solely liable to you for the performance of all of the obligations assumed by us under or in respect of the Agreement;
- (b) we irrevocably and unconditionally instruct and authorise you (despite any previous instructions which we may have given to the contrary) to pay any monies payable by you to us under the Agreement to such bank account as the Lender may from time to time specify in writing;
- (c) we have agreed not to rescind or otherwise terminate the Agreement without the prior written consent of the Lender,
- (d) we agree that:
 - (i) none of the instructions, authorisations and confirmations in this notice can be revoked or varied in any way except with the Lender's prior written consent, and
 - (ii) you are authorised to disclose any information in relation to the Agreement to the Lender at the Lender's request.

Please acknowledge receipt of this notice, and confirm your agreement to it, by signing the acknowledgement on the enclosed copy letter and returning it to the Lender, at [●] marked for the attention of [●].

This letter is governed by, and shall be construed in accordance with, English law

Yours faithfully

..
[Name of relevant Chargor]
By: *[Name of signatory]*

[On copy letter only.]

To: **[Lender]**

We acknowledge receipt of a notice dated [●] 200[●] addressed to us by **[Name of relevant Chargor]** (the "Chargor") regarding an agreement dated [●] 2015 between us and the Chargor (as amended or novated from time to time, the "Agreement").

We confirm that:

- (a) we consent to the assignment of the Agreement and will comply with the terms of that notice;
- (b) we have not, as at the date of this acknowledgement, received any notice that any third party has or will have any right in, or has made or will be making any claim or demand or taking any action in respect of, the rights of the Chargor under or in respect of the Agreement;
- (c) if the Chargor is in breach of any of its obligations, express or implied, under the Agreement or if any event occurs which would permit us to terminate, cancel or surrender the Agreement we will:
 - (i) immediately on becoming aware of it, give you written notice of that breach, and
 - (ii) accept as an adequate remedy for that breach, performance by you of those obligations within 30 days of that notice;
- (d) we confirm that no waiver of any of the Chargor's rights under and no amendment, novation, rescission or other termination by the Chargor of, the Agreement shall be effective without the prior written consent of the Lender; and
- (e) we confirm that we shall not exercise any right of combination, consolidation or set-off which we may have in respect of any debt owed to us by the Chargor and we shall send you copies of all statements, orders and notices given by us relating to that debt.

.....
[Name of other party]

By: [Name of signatory]

Dated:

SCHEDULE 4
NOTICE OF ASSIGNMENT OF INSURANCE

[On relevant Chargor's notepaper]

To: *[Name and address of insurer]*

[Date]

Dear Sirs

Policy number [●]

We give you notice that by a Debenture (the "Debenture") dated [●] 2015 and entered into by us in favour of Knight Therapeutics Inc (as Lender, as defined in the Debenture), we have assigned all our rights in the insurance policy, brief details of which are set out below (the "Policy") and all monies which may be payable to or received by us under it.

Please note the following:

- (a) we irrevocably and unconditionally instruct and authorise you (despite any previous instructions which we may have given to the contrary) to continue to pay all monies payable by you to us under the Policy, including the proceeds of all claims, to us unless the Lender notified you that an Event of Default is continuing, in which case you should comply with the instructions of the Lender,
- (b) we agree that:
 - (i) none of the instructions, authorisations and confirmations in this notice can be revoked or varied in any way except with the Lender's prior written consent; and
 - (ii) you are authorised to disclose any information in relation to the Policy to the Lender at the Lender's request.

Please acknowledge receipt of this notice, and confirm your agreement to it, by signing the acknowledgement on the enclosed copy letter and returning it to the Lender, at [●] marked for the attention of [●].

This letter is governed by, and shall be construed in accordance with, English law.

Yours faithfully

.....
[Name of relevant Chargor]
By: *[Name of signatory]*

Details of Policy

Name of insured. [•]

Nature of policy: [•]

Policy number: [•]

Expiry date: [•]

[On copy letter only]

To ***Lender***

We acknowledge receipt of a notice dated [•] 200[•] addressed to us by *[Name of relevant Chargor]* (the "Chargor") regarding the Policy (as defined in that notice)

.....
[Name of insurer]
By: *[Name of signatory]*

Dated:

**SCHEDULE 5
NOTICE OF CHARGE**

[On relevant Chargor's notepaper]

To: *[Name and address of other bank]*

[Date]

Dear Sirs

Account number: [●]

We refer to Account number. [●] (the "Account").

We give you notice that by a Debenture (the "Debenture") dated [●] 2015 and entered into by us in favour of Knight Therapeutics Inc. (as Lender, as defined in the Debenture) we have charged all our rights in any credit balances on the Account (the "Balances") and the indebtedness represented by the Account.

We irrevocably and unconditionally instruct and authorise you (despite any previous instructions which we may have given to the contrary):

- (a) that we are entitled to continue to exercise all of our rights in any credit balances on any bank accounts and the indebtedness represented by them, including (without limitation) the right to withdraw amounts from any bank account until you receive notice from the Lender that an Event of Default is continuing,
- (b) to disclose to the Lender (without any reference to or further authority from us and without any enquiry by you as to the justification for the disclosure), any information relating to the Account which the Lender may, at any time and from time to time, request;
- (c) at any time and from time to time on receipt by you of any written instruction from the Lender confirming that an Event of Default is continuing, to release any amount of the Balances and to act in accordance with that instruction (without any reference to or further authority from us and without any enquiry by you as to the justification for the instruction or the validity of the same).

We agree that:

- (i) none of the instructions, authorisations and confirmations in this notice can be revoked or varied in any way except with the Lender's prior written consent, and
- (ii) you are authorised to disclose any information in relation to the Account to the Lender at the Lender's request.

Please acknowledge receipt of this notice, and confirm your agreement to it, by signing the acknowledgement on the enclosed copy letter and returning it to the Lender at [●] marked for the attention of [●].

This letter is governed by, and shall be construed in accordance with, English law.

Yours faithfully

.....
[Name of relevant Chargor]
By: *[Name of signatory]*

[On copy letter only:]

To: ***Lender***

We acknowledge receipt of a notice dated [●] 200[●] addressed to us by ***[Name of relevant Chargor]*** (the "Chargor") regarding Account number: [●] (the "Account").

.....
for and on behalf of
[Name of bank]
By: *[Name of signatory]*

Dated:

SCHEDULE 6
INTELLECTUAL PROPERTY

Patents and patent applications

Chargor	Patent
Sequessome Technology Holdings Limited	European patent application no. EP2437726
Sequessome Technology Holdings Limited	European patent application no EP2836203
Sequessome Technology Holdings Limited	European patent application no. EP2849721
Pro Bono Bio International Trading Ltd	PCT application no. WO2015014965
Sequessome Technology Holdings Limited	European patent application no EP2849722
Sequessome Technology Holdings Limited	European patent application no EP2467170
Sequessome Technology Holdings Limited	European patent application no. EP2830630
Cantab Biopharmaceuticals Patents Limited	European patent application no. EP2838566
Cantab Biopharmaceuticals Patents Limited (by virtue of a deed of assignment dated 27 March 2015 between Recoly N.V. and Cantab Biopharmaceuticals Patents Limited)	European patent no EP1079805
Cantab Biopharmaceuticals Patents Limited (by virtue of a deed of assignment dated 27 March 2015 between Recoly N.V. and Cantab Biopharmaceuticals Patents Limited)	European patent no. EP1633440

Trade marks

Owner	Trade mark number	Country	Classes
Pro Bono Bio Entrepreneur Limited	UK00002584168	UK	Class 10 Surgical and medical apparatus and instruments; artificial limbs and eyes; orthopaedic articles, suture materials; apparatus for carrying out diagnostic tests for medical purposes; syringes; injectors; medical thermometers; blood sugar meters, fibrin scaffolds, stents, x-ray

			machines.
Pro Bono Bio Entrepreneur Limited	UK00002584101	UK	<p>Class 5</p> <p>Pharmaceutical preparations and substances; veterinary and sanitary preparations and substances; dietetic substances adapted for medical use; chemical preparations for pharmaceutical purposes; diagnostic preparations and substances, all for in vivo use; micro-organisms and preparation of micro-organisms, all for medical and veterinary use; infants and invalids foods, nutritional supplements included in Class 5 for humans and animals; vitamins, minerals and mineral salts; herbal preparations; medicated confectionery; enzyme preparations; pharmaceuticals in the field of oncology, cardiovascular disease, respiratory disease, inflammation, infection, gastrointestinal diseases and central nervous system diseases; diagnostic preparations for medical and veterinary use; topical and parenteral preparations of vesicles; chemical preparations in the form of vesicles for medical and veterinary purposes; chemical membranes and chemical aggregates for medical and veterinary purposes; preparations of arachidonic acids; dispersions and dry preparations of liposomal active substance carriers for pharmaceutical, cosmetic and veterinary substances, cosmeceutical preparations for medical use; local anaesthetics; steroids; anti-inflammatory drugs; pharmaceuticals for the treatment of nail fungal infections; vaccines, immunotherapeutic vaccines.</p> <p>Class 10</p> <p>Surgical, medical and dental apparatus and instruments; artificial limbs, eyes and teeth; orthopaedic</p>

			articles; suture materials; apparatus for carrying out diagnostic tests for medical purposes; syringes; injectors; medical thermometers; blood sugar meters; fibrin scaffolds; stents; x-ray machines
Pro Bono Bio Entrepreneur Limited	UK00002584105	UK	<p>Class 10</p> <p>Surgical and medical apparatus and instruments, artificial limbs and eyes; orthopaedic articles; suture materials; apparatus for carrying out diagnostic tests for medical purposes; syringes; injectors; medical thermometers; blood sugar meters; fibrin scaffolds; stents; x-ray machines.</p>
Pro Bono Bio Entrepreneur Limited	UK0002585425	UK	<p>Class 1</p> <p>Lipids and surfactants for use in industry and science ;surfactants and lipids for use in personal care products, chemical products for in vitro or in vivo use in research and development.</p> <p>Class 5</p> <p>Pharmaceutical preparations and substances; veterinary and sanitary preparations and substances; chemical preparations for pharmaceutical purposes; diagnostic preparations and substances, all for in vivo use; pharmaceuticals in the field of osteoarthritis, oncology, cardiovascular disease, respiratory disease, inflammation, infection, gastrointestinal diseases and central nervous system diseases; diagnostic preparations for medical and veterinary use; topical and parenteral preparations of vesicles; chemical preparations in the form of vesicles for medical and veterinary purposes, chemical membranes and chemical aggregates for medical and veterinary purposes; preparations of arachidonic acids, dispersions and</p>

		<p>dry preparations of liposomal active substance carriers for pharmaceutical, cosmetic and veterinary substances; cosmeceutical preparations for medical use; local anaesthetics; steroids; anti-inflammatory drugs; pharmaceuticals for the treatment of nail fungal infections; vaccines, immunotherapeutic vaccines, lipids for topical and parenteral use; creams, dispersions, lotions, ointments, gels, solutions, sprays, lacquers and film forming solution for the treatment of pain or inflammation, surfactants for use in the treatment of or prevention of cancer, infectious disease, fungal diseases, disease caused by parasites, eye disease, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, inherited disease, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases and reproductive system disorders, the treatment of inflammation, asthma, atopic eczema, dishydrotic hand eczema, plaque type psoriasis, seborrhoeic eczema, acne vulgaris, bronchospasm, atherothrombotic cardiovascular disorders, venous thrombotic disorders, pain, dysmenorrhea, hypercholesterolemia, hypertriglyceridemia, fatty acid metabolism, metal or other toxicity, Alzheimer's disease, gout or macular degeneration, such as AMD, or fungal infection and disorders related to fatty acid deficiencies.</p> <p>Class 10</p> <p>Medical devices for topical use in the treatment of pain, molecular filtering devices for medical use; medical, veterinary and surgical apparatus, instruments and devices; inhalers,</p>
--	--	--

			<p>injection apparatus, instruments and devices, apparatus, instruments and devices for dispensing medical, surgical and veterinary preparations, dispersions, creams, powders, tablets and pills; instruments and devices for the administration of pain relief therapy and prophylaxis preparations and substances, parts and fittings for all of the aforesaid.</p>
Pro Bono Bio Entrepreneur Limited	UK00002585684	UK	<p>lass 5</p> <p>Pharmaceutical preparations and substances; veterinary and sanitary preparations and substances; chemical preparations for pharmaceutical purposes; pharmaceuticals in the field of osteoarthritis , oncology, cardiovascular disease, respiratory disease, inflammation, infection, gastrointestinal diseases and central nervous system diseases; diagnostic preparations for medical and veterinary use; topical and parenteral preparations of vesicles; chemical preparations in the form of vesicles for medical and veterinary purposes; chemical membranes and chemical aggregates for medical and veterinary purposes; preparations of arachidonic acids; dispersions and dry preparations of liposomal active substance carriers for pharmaceutical, cosmetic and veterinary substances; cosmeceutical preparations for medical use; local anaesthetics; steroids; anti-inflammatory drugs; pharmaceuticals for the treatment of nail fungal infections; vaccines; immunotherapeutic vaccines; lipids for topical and parenteral use; creams, dispersions, lotions, ointments, gels, solutions, sprays, lacquers and film forming solution for the treatment of pain or inflammation; surfactants for use in the treatment of or prevention of</p>

			<p>cancer, infectious disease, fungal diseases, disease caused by parasites, eye disease, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, inherited disease, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases and reproductive system disorders, the treatment of inflammation, asthma, atopic eczema, dishydrotic hand eczema, plaque type psoriasis, seborrheic eczema, acne vulgaris, bronchospasm, atherothrombotic cardiovascular disorders, venous thrombotic disorders, pain, dysmenorrhea, hypercholesterolemia, hypertriglyceridemia, fatty acid metabolism, metal or other toxicity, alzheimer's disease, gout or macular degeneration, such as AMD, or fungal infection ,and disorders related to fatty acid deficiencies</p> <p>Class 10</p> <p>Medical devices for topical use in allowing subcutaneous absorption for the treatment of pain; molecular filtering devices for medical use; medical, veterinary and surgical apparatus, instruments and devices; inhalers; injection apparatus, instruments and devices; apparatus, instruments and devices for dispensing medical, surgical and veterinary preparations, dispersions, creams, powders, tablets and pills; instruments and devices for the administration of pain relief therapy and prophylaxis preparations and substances; parts and fittings for all of the aforesaid.</p>
Pro Bono Bio Entrepreneur Limited	UK00002586960	UK	<p>Class 5</p> <p>Pharmaceutical preparations and substances; veterinary and sanitary</p>

		<p>preparations and substances; chemical preparations for pharmaceutical purposes; pharmaceuticals in the field of osteoarthritis, oncology, cardiovascular disease, respiratory disease, inflammation, infection, gastrointestinal diseases and central nervous system diseases; diagnostic preparations for medical and veterinary use; topical and parenteral preparations of vesicles; chemical preparations in the form of vesicles for medical and veterinary purposes; chemical membranes and chemical aggregates for medical and veterinary purposes; preparations of arachidonic acids; dispersions and dry preparations of liposomal active substance carriers for pharmaceutical, cosmetic and veterinary substances; cosmeceutical preparations for medical use; anti- inflammatory drugs; lipids for topical and parenteral use; creams, dispersions, lotions, ointments, gels, solutions, sprays, lacquers and film forming solution for the treatment of pain or inflammation; surfactants for use in the treatment of or prevention of cancer, infectious disease, fungal diseases, disease caused by parasites, eye disease, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, inherited disease, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases and reproductive system disorders, the treatment of inflammation, asthma, atopic eczema, dishydrotic hand eczema, plaque type psoriasis, seborrheic eczema, acne vulgaris, bronchospasm, atherothrombotic cardiovascular disorders, venous thrombotic disorders, pain, dysmenorrhea, hypercholesterolemia, hypertriglyceridemia, fatty acid</p>
--	--	---

			<p>metabolism, metal or other toxicity, alzheimer's disease, gout or macular degeneration, such as AMD, or fungal infection, and disorders related to fatty acid deficiencies.</p> <p>Class 10</p> <p>Medical devices for topical use in allowing subcutaneous absorption for the treatment of pain; molecular filtering devices for medical use, medical, veterinary and surgical apparatus, instruments and devices, apparatus, instruments and devices for dispensing medical, surgical and veterinary preparations, dispersions, creams, powders, tablets and pills, instruments and devices for the administration of therapy and prophylaxis preparations and substances; parts and fittings for all of the aforesaid.</p>
Pro Bono Bio Entrepreneur Limited	UK00002586860	UK	<p>Class 5</p> <p>Pharmaceutical preparations and substances; veterinary and sanitary preparations and substances; chemical preparations for pharmaceutical purposes; pharmaceuticals in the field of osteoarthritis, oncology, cardiovascular disease, respiratory disease, inflammation, infection, gastrointestinal diseases and central nervous system diseases; diagnostic preparations for medical and veterinary use; topical and parenteral preparations of vesicles; chemical preparations in the form of vesicles for medical and veterinary purposes; chemical membranes and chemical aggregates for medical and veterinary purposes; preparations of arachidonic acids; dispersions and dry preparations of liposomal active substance carriers for pharmaceutical, cosmetic and veterinary substances; cosmeceutical</p>

		<p>preparations for medical use; anti-inflammatory drugs; lipids for topical and parenteral use; creams, dispersions, lotions, ointments, gels, solutions, sprays, lacquers and film forming solution for the treatment of pain or inflammation; surfactants for use in the treatment of or prevention of cancer, infectious disease, fungal diseases, disease caused by parasites, eye disease, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, inherited disease, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases and reproductive system disorders, the treatment of inflammation, asthma, atopic eczema, dishydrotic hand eczema, plaque type psoriasis, seborrheic eczema, acne vulgaris, bronchospasm, atherothrombotic cardiovascular disorders, venous thrombotic disorders, pain, dysmenorrhea, hypercholesterolemia, hypertriglyceridemia, fatty acid metabolism, metal or other toxicity, alzheimer's disease, gout or macular degeneration, such as AMD, or fungal infection, and disorders related to fatty acid deficiencies.</p> <p>Class 10</p> <p>Medical devices for topical use in allowing subcutaneous absorption for the treatment of pain; molecular filtering devices for medical use; medical, veterinary and surgical apparatus, instruments and devices; apparatus, instruments and devices for dispensing medical, surgical and veterinary preparations, dispersions, creams, powders, tablets and pills; instruments and devices for the administration of therapy and prophylaxis preparations and substances; parts and fittings for all</p>
--	--	--

			of the aforesaid.
Pro Bono Bio Entrepreneur Limited	EU010104669	UK	<p>Class 1</p> <p>Dispersions and dry preparations of liposomal active substance carriers for pharmaceutical, cosmetic and veterinary substances.</p> <p>Class 5</p> <p>Pharmaceutical preparations and substances; veterinary and sanitary preparations and substances, dietetic substances adapted for medical use; chemical preparations for pharmaceutical purposes; diagnostic preparations and substances, all for in vivo use; micro-organisms and preparation of micro-organisms, all for medical and veterinary use; infants and invalids foods; nutritional supplements included in Class 5 for humans and animals; vitamins, minerals and mineral salts; herbal preparations; medicated confectionery; enzyme preparations; pharmaceuticals in the field of oncology, cardiovascular disease, respiratory disease, inflammation, infection, gastrointestinal diseases and central nervous system diseases; diagnostic preparations for medical and veterinary use; topical and parenteral preparations of vesicles; chemical preparations in the form of vesicles for medical and veterinary purposes; chemical membranes and chemical aggregates for medical and veterinary purposes; preparations of arachidonic acids; cosmeceutical preparations for medical use; local anaesthetics; steroids; anti-inflammatory drugs; pharmaceuticals for the treatment of nail fungal infections; vaccines; immunotherapeutic vaccines; topical and parenteral preparations of vesicles; chemical preparations in the form of vesicles for medical and</p>

			<p>veterinary purposes, chemical membranes and chemical aggregates for medical and veterinary purposes; preparations of arachidonic acids; dispersions and dry preparations of liposomal active substance carriers for pharmaceutical, cosmetic and veterinary substances; cosmeceutical preparations for medical use; local anaesthetics; steroids; anti-inflammatory drugs; pharmaceuticals for the treatment of nail fungal infections; vaccines; immunotherapeutic vaccines; lipids for topical and parenteral use; creams, dispersions, lotions, ointments, gels, solutions, sprays, lacquers and film forming solution for the treatment of pain or inflammation, surfactants for use in the treatment of or prevention of cancer, infectious disease, fungal diseases, disease caused by parasites, eye disease, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, inherited disease, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases and reproductive system disorders, the treatment of inflammation, asthma, atopic eczema, dishydrotic hand eczema, plaque type psoriasis, seborrhoeic eczema, acne vulgaris, bronchospasm, atherothrombotic cardiovascular disorders, venous thrombotic disorders, pain, dysmenorrhea, hypercholesterolemia, hypertriglyceridemia, fatty acid metabolism, metal or other toxicity, Alzheimer's disease, gout or macular degeneration, such as AMU, or fungal infection and disorders related to fatty acid deficiencies.</p> <p>Class 10</p> <p>Surgical, medical and dental</p>
--	--	--	---

			<p>apparatus and instruments; artificial limbs, eyes and teeth; orthopaedic articles; suture materials; apparatus for carrying out diagnostic tests for medical purposes, syringes; injectors; medical thermometers; blood sugar meters; fibrin scaffolds; stents; x-ray machines; medical devices for topical use in the treatment of pain; molecular filtering devices for medical use; medical, veterinary and surgical apparatus, instruments and devices; inhalers, injection apparatus, instruments and devices; apparatus, instruments and devices for dispensing medical, surgical and veterinary preparations, dispersions, creams, powders, tablets and pills; instruments and devices for the administration of pain relief therapy and prophylaxis preparations and substances; parts and fittings for all of the aforesaid</p> <p>Class 42</p> <p>Scientific and technological services and research and design relating thereto, industrial analysis and research services; design and development of computer hardware and software, medical research and analysis; the provision of technical information on pharmaceutical products and services through an on-line computer network and research and design relating thereto; industrial analysis and research services; pharmaceutical research services; services for assessing the efficiency of pharmaceuticals.</p>
Pro Bono Bio Entrepreneur Limited	EU010106219	UK	<p>Class 1</p> <p>Lipids and surfactants for use in industry and science; surfactants and lipids for use in personal care products, chemical products for in vitro or in vivo use in research and development; dispersions and dry</p>

		<p>preparations of liposomal active substance carriers for pharmaceutical, cosmetic and veterinary substances.</p> <p>Class 5</p> <p>Pharmaceutical preparations and substances; veterinary and sanitary preparations and substances; chemical preparations for pharmaceutical purposes; diagnostic preparations and substances, all for in vivo use; pharmaceuticals in the field of osteoarthritis, oncology, cardiovascular disease, respiratory disease, inflammation, infection, gastrointestinal diseases and central nervous system diseases; diagnostic preparations for medical and veterinary use; topical and parenteral preparations of vesicles; chemical preparations in the form of vesicles for medical and veterinary purposes; chemical membranes and chemical aggregates for medical and veterinary purposes; preparations of arachidonic acids; cosmeceutical preparations for medical use; local anaesthetics, steroids; anti-inflammatory drugs; pharmaceuticals for the treatment of nail fungal infections; vaccines, immunotherapeutic vaccines; lipids for topical and parenteral use; creams, dispersions, lotions, ointments, gels, solutions, sprays, lacquers and film forming solution for the treatment of pain or inflammation; surfactants for use in the treatment of or prevention of cancer, infectious disease, fungal diseases, disease caused by parasites, eye disease, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, inherited disease, single gene disorders, diseases of the mouth, teeth, skin,</p>
--	--	--

		<p>hair and ear, bone and blood diseases and reproductive system disorders, the treatment of inflammation, asthma, atopic eczema, dishydrotic hand eczema, plaque type psoriasis, seborrhoeic eczema, acne vulgaris, bronchospasm, atherothrombotic cardiovascular disorders, venous thrombotic disorders, pain, dysmenorrhealhypercholesterolemia, hypertriglyceridemia, fatty acid metabolism, metal or other toxicity, Alzheimer's disease, gout or macular degeneration, such as AMU, or fungal infection and disorders related to fatty acid deficiencies.</p> <p>Class 10</p> <p>Medical devices for topical use in the treatment of pain; apparatus, instruments and devices for dispensing dispersions, creams, powders, tablets and pills; instruments and devices for the administration of pain relief therapy and prophylaxis preparations and substances</p>
Pro Bono Bio Entrepreneur Limited	EU010136364	<p>Class 1</p> <p>Dispersions and dry preparations of liposomal active substance carriers for pharmaceutical, cosmetic and veterinary substances.</p> <p>Class 5</p> <p>Pharmaceutical preparations and substances, veterinary and sanitary preparations and substances; chemical preparations for pharmaceutical purposes; topical and parenteral preparations of vesicles; chemical preparations in the form of vesicles for medical and veterinary purposes; chemical membranes and chemical aggregates for medical and veterinary purposes, preparations of arachidonic acids, cosmeceutical preparations for medical use; local</p>

			<p>anaesthetics; lipids for topical and parenteral use, creams, dispersions, lotions, ointments, gels, solutions, sprays, lacquers and film forming solution for the treatment of dermal conditions associated with the surface or upper layers of the skin; surfactants for use in the treatment of diseases affecting the immune system, inflammatory diseases, diseases of the skin, hair and ear, the treatment of inflammation, atopic eczema, dishydrotic hand eczema, plaque type psoriasis, seborrhoeic eczema, acne vulgaris, pain, or fungal infection and disorders related to the skin.</p> <p>Class 10</p> <p>Medical devices for topical use in the treatment of dermal conditions associated with the surface or upper layers of the skin; molecular filtering devices for medical use; medical, veterinary and surgical apparatus, instruments and devices; inhalers; injection apparatus, instruments and devices; apparatus, instruments and devices for dispensing medical, surgical and veterinary preparations, dispersions, creams, powders, tablets and pills; instruments and devices for the administration of skin disease therapy and prophylaxis preparations and substances; parts and fittings for all of the aforesaid</p> <p>Class 42</p> <p>Scientific and medical research and development; pharmaceutical and drug delivery research services; advisory services relating to pharmaceuticals and drug delivery products and clinical trials, conducting clinical trials</p>
Pro Bono Bio Entrepreneur Limited	EU010134351		<p>Class 1</p> <p>Lipids and surfactants for use in</p>

		<p>industry and science; surfactants and lipids for use in personal care products, chemical products for in vitro or in vivo use in research and development; dispersions and dry preparations of liposomal active substance carriers for pharmaceutical, cosmetic and veterinary substances.</p> <p>Class 5</p> <p>Pharmaceutical preparations and substances; veterinary and sanitary preparations and substances; chemical preparations for pharmaceutical purposes; diagnostic preparations and substances, all for in vivo use; pharmaceuticals in the field of osteoarthritis, oncology, cardiovascular disease, respiratory disease, inflammation, infection, gastrointestinal diseases and central nervous system diseases; diagnostic preparations for medical and veterinary use; topical and parenteral preparations of vesicles; chemical preparations in the form of vesicles for medical and veterinary purposes; chemical membranes and chemical aggregates for medical and veterinary purposes; preparations of arachidonic acids, cosmeceutical preparations for medical use; local anaesthetics; steroids; anti-inflammatory drugs; pharmaceuticals for the treatment of nail fungal infections; vaccines, immunotherapeutic vaccines; lipids for topical and parenteral use; creams, dispersions, lotions, ointments, gels, solutions, sprays, lacquers and film forming solution for the treatment of pain or inflammation; surfactants for use in the treatment of or prevention of cancer, infectious disease, fungal diseases, disease caused by parasites, eye disease, diseases of the central and peripheral nervous systems,</p>
--	--	--

		<p>cardiovascular disease, diseases affecting the immune system, inflammatory diseases, inherited disease, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases and reproductive system disorders, the treatment of inflammation, asthma, atopic eczema, dishydrotic hand eczema, plaque type psoriasis, seborrhoeic eczema, acne vulgaris, bronchospasm, atherothrombotic cardiovascular disorders, venous thrombotic disorders, pain, dysmenorrhea hypercholesterolemia, hypertriglyceridemia, fatty acid metabolism, metal or other toxicity, Alzheimer's disease, gout or macular degeneration, such as AMD, or fungal infection and disorders related to fatty acid deficiencies</p> <p>Class 10</p> <p>Medical devices for topical use in the treatment of pain; apparatus, instruments and devices for dispensing dispersions, creams, powders, tablets and pills, instruments and devices for the administration of pain relief therapy and prophylaxis preparations and substances.</p>
Pro Bono Bio Entrepreneur Limited	EU010134451	<p>Class 1</p> <p>Dispersions and dry preparations of liposomal active substance carriers for pharmaceutical, cosmetic and veterinary substances.</p> <p>Class 5</p> <p>Pharmaceutical preparations and substances; veterinary and sanitary preparations and substances; chemical preparations for pharmaceutical purposes; pharmaceuticals in the field of osteoarthritis, oncology, cardiovascular disease, respiratory</p>

		<p>disease, inflammation, infection, gastrointestinal diseases and central nervous system diseases; diagnostic preparations for medical and veterinary use; topical and parenteral preparations of vesicles; chemical preparations in the form of vesicles for medical and veterinary purposes; chemical membranes and chemical aggregates for medical and veterinary purposes; preparations of arachidonic acids; cosmeceutical preparations for medical use, anti-inflammatory drugs, lipids for topical and parenteral use; creams, dispersions, lotions, ointments, gels, solutions, sprays, lacquers and film forming solution for the treatment of pain or inflammation, surfactants for use in the treatment of or prevention of cancer, infectious disease, fungal diseases, disease caused by parasites, eye disease, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, inherited disease, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases and reproductive system disorders, the treatment of inflammation, asthma, atopic eczema, dishydrotic hand eczema, plaque type psoriasis, seborrheic eczema, acne vulgaris, bronchospasm, atherothrombotic cardiovascular disorders, venous thrombotic disorders, pain, dysmenorrhea hypercholesterolemia, hypertriglyceridemia, fatty acid metabolism, metal or other toxicity, alzheimer's disease, gout or macular degeneration, such as AMD, or fungal infection, and disorders related to fatty acid deficiencies</p> <p>Class 10</p> <p>Medical devices for topical use in allowing subcutaneous absorption for</p>
--	--	---

			<p>the treatment of pain; molecular filtering devices for medical use; medical, veterinary and surgical apparatus, instruments and devices, apparatus, instruments and devices for dispensing medical, surgical and veterinary preparations, dispersions, creams, powders, tablets and pills; instruments and devices for the administration of therapy and prophylaxis preparations and substances; parts and fittings for all of the aforesaid.</p> <p>Class 42</p> <p>Scientific and medical research and development, pharmaceutical and drug delivery research services, advisory services relating to pharmaceuticals and drug delivery products and clinical trials, conducting clinical trials.</p>
Pro Bono Bio Entrepreneur Limited	EU010134799		<p>Class 1</p> <p>Dispersions and dry preparations of liposomal active substance carriers for pharmaceutical, cosmetic and veterinary substances.</p> <p>Class 5</p> <p>Pharmaceutical preparations and substances, veterinary and sanitary preparations and substances; chemical preparations for pharmaceutical purposes; pharmaceuticals in the field of osteoarthritis, oncology, cardiovascular disease, respiratory disease, inflammation, infection, gastrointestinal diseases and central nervous system diseases; diagnostic preparations for medical and veterinary use; topical and parenteral preparations of vesicles; chemical preparations in the form of vesicles for medical and veterinary purposes; chemical membranes and chemical aggregates for medical and</p>

		<p>veterinary purposes; preparations of arachidonic acids; cosmeceutical preparations for medical use; anti-inflammatory drugs; lipids for topical and parenteral use; creams, dispersions, lotions, ointments, gels, solutions, sprays, lacquers and film forming solution for the treatment of pain or inflammation; surfactants for use in the treatment of or prevention of cancer, infectious disease, fungal diseases, disease caused by parasites, eye disease, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, inherited disease, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases and reproductive system disorders, the treatment of inflammation, asthma, atopic eczema, dishydrotic hand eczema, plaque type psoriasis, seborrheic eczema, acne vulgaris, bronchospasm, atherothrombotic cardiovascular disorders, venous thrombotic disorders, pain, dysmenorrhea hypercholesterolemia, hypertriglyceridemia, fatty acid metabolism, metal or other toxicity, alzheimer's disease, gout or macular degeneration, such as AMD, or fungal infection, and disorders related to fatty acid deficiencies.</p> <p>Class 10</p> <p>Medical devices for topical use in allowing subcutaneous absorption for the treatment of pain; molecular filtering devices for medical use; medical, veterinary and surgical apparatus, instruments and devices; apparatus, instruments and devices for dispensing medical, surgical and veterinary preparations, dispersions, creams, powders, tablets and pills; instruments and devices for the administration of therapy and</p>
--	--	---

		<p>prophylaxis preparations and substances; parts and fittings for all of the aforesaid.</p> <p>Class 42</p> <p>Scientific and medical research and development; pharmaceutical and drug delivery research services, advisory services relating to pharmaceuticals and drug delivery products and clinical trials, conducting clinical trials.</p>
Pro Bono Bio Entrepreneur Limited	EU010136208	<p>List of goods and services</p> <p>Class 1</p> <p>Dispersions and dry preparations of liposomal active substance carriers for pharmaceutical, cosmetic and veterinary substances</p> <p>Class 5</p> <p>Pharmaceutical preparations and substances; veterinary and sanitary preparations and substances; chemical preparations for pharmaceutical purposes; topical and parenteral preparations of vesicles; chemical preparations in the form of vesicles for medical and veterinary purposes; chemical membranes and chemical aggregates for medical and veterinary purposes; preparations of arachidonic acids; cosmeceutical preparations for medical use; local anaesthetics; lipids for topical and parenteral use; creams, dispersions, lotions, ointments, gels, solutions, sprays, lacquers and film forming solution for the treatment of dermal conditions associated with the surface or upper layers of the skin; surfactants for use in the treatment of diseases affecting the immune system, inflammatory diseases, diseases of the skin, hair and ear, the treatment of inflammation, atopic eczema, dishydrotic hand eczema,</p>

			<p>plaque type psoriasis, seborrhoic eczema, acne vulgaris, pain, or fungal infection and disorders related to the skin.</p> <p>Class 10</p> <p>Medical devices for topical use in the treatment of dermal conditions associated with the surface or upper layers of the skin; molecular filtering devices for medical use; medical, veterinary and surgical apparatus, instruments and devices; inhalers, injection apparatus, instruments and devices; apparatus, instruments and devices for dispensing medical, surgical and veterinary preparations, dispersions, creams, powders, tablets and pills; instruments and devices for the administration of skin disease therapy and prophylaxis preparations and substances; parts and fittings for all of the aforesaid.</p> <p>Class 42</p> <p>Scientific and medical research and development, pharmaceutical and drug delivery research services; advisory services relating to pharmaceuticals and drug delivery products and clinical trials, conducting clinical trials.</p>
Pro Bono Bio Entrepreneur Limited	EU003884798		<p>Class 5</p> <p>Pharmaceutical, sanitary preparations, dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants.</p>
Pro Bono Bio Entrepreneur Limited	EU010244606		<p>Class 5</p> <p>Pharmaceutical preparations and substances; veterinary and sanitary preparations and substances, chemical preparations for pharmaceutical purposes; topical and</p>

		<p>parenteral preparations of vesicles, chemical preparations in the form of vesicles for medical and veterinary purposes; chemical membranes and chemical aggregates for medical and veterinary purposes, preparations of arachidonic acids; dispersions and dry preparations of liposomal active substances for use as a pharmaceutical, cosmetic and veterinary substance carrier; cosmeceutical preparations for medical use; local anaesthetics; lipids for topical and parenteral use; creams, dispersions, lotions, ointments, gels, solutions, sprays, lacquers and film forming solution for the treatment of dermal conditions associated with deep layers of the skin beneath the epidermis; surfactants for use in the treatment of diseases affecting the immune system, inflammatory diseases, diseases of the skin, hair and ear, the treatment of inflammation, atopic eczema, dishydrotic hand eczema, plaque type psoriasis, seborrhoeic eczema, acne vulgaris, pain, or fungal infection and disorders related to the skin</p> <p>Class 10</p> <p>Medical devices for topical use in the treatment of dermal conditions associated with deep layers of the skin beneath the epidermis; molecular filtering devices for medical use; medical, veterinary and surgical apparatus, instruments and devices; inhalers; injection apparatus, instruments and devices; apparatus, instruments and devices for dispensing medical, surgical and veterinary preparations, dispersions, creams, powders, tablets and pills; instruments and devices for the administration of skin disease therapy and prophylaxis preparations</p>
--	--	--

			<p>and substances; parts and fittings for all of the aforesaid.</p> <p>Class 42</p> <p>Scientific and medical research and development; pharmaceutical and drug delivery research services; advisory services relating to pharmaceuticals and drug delivery products and clinical trials, conducting clinical trials</p>
Pro Bono Bio Entrepreneur Limited	UK00002600071	UK	<p>Class 5</p> <p>Pharmaceutical preparations and substances; veterinary and sanitary preparations and substances, chemical preparations for pharmaceutical purposes; topical and parenteral preparations of vesicles; chemical preparations in the form of vesicles for medical and veterinary purposes; chemical membranes and chemical aggregates for medical and veterinary purposes; preparations of arachidonic acids; dispersions and dry preparations of liposomal active substances for use as a pharmaceutical, cosmetic and veterinary substance carrier; cosmeceutical preparations for medical use, local anaesthetics; lipids for topical and parenteral use; creams, dispersions, lotions, ointments, gels, solutions, sprays, lacquers and film forming solution for the treatment of dermal conditions associated with deep layers of the skin beneath the epidermis; surfactants for use in the treatment of diseases affecting the immune system, inflammatory diseases, diseases of the skin, hair and ear, the treatment of inflammation, atopic eczema, dishydrotic hand eczema, plaque type psoriasis, seborrhoeic eczema, acne vulgaris, pain, or fungal infection and disorders related to the</p>

			<p>skin.</p> <p>Class 10</p> <p>Medical devices for topical use in the treatment of dermal conditions associated with deep layers of the skin beneath the epidermis; molecular filtering devices for medical use; medical, veterinary and surgical apparatus, instruments and devices; inhalers; injection apparatus, instruments and devices, apparatus, instruments and devices for dispensing medical, surgical and veterinary preparations, dispersions, creams, powders, tablets and pills; instruments and devices for the administration of skin disease therapy and prophylaxis preparations and substances; parts and fittings for all of the aforesaid.</p> <p>Class 42</p> <p>Scientific and medical research and development, pharmaceutical and drug delivery research services; advisory services relating to pharmaceuticals and drug delivery products and clinical trials, conducting clinical trials.</p>
--	--	--	---

Pro Bono Bio Entrepreneur Limited	UK00002600134	UK	<p>Class 5</p> <p>Pharmaceutical preparations and substances; veterinary and sanitary preparations and substances; dietetic substances adapted for medical use, chemical preparations for pharmaceutical purposes; diagnostic preparations and substances, all for in vivo use; micro-organisms and preparation of micro-organisms, all for medical and veterinary use; infants and invalids foods; nutritional supplements included in Class 5 for humans and animals, vitamins, minerals and mineral salts; herbal preparations; medicated confectionery; enzyme preparations; pharmaceuticals in the field of oncology, cardiovascular disease, respiratory disease, inflammation, infection, gastrointestinal diseases and central nervous system diseases; diagnostic preparations for medical and veterinary use; topical and parenteral preparations of vesicles; chemical preparations in the form of vesicles for medical and veterinary purposes; chemical membranes and chemical aggregates for medical and veterinary purposes; preparations of arachidonic acids; dispersions and dry preparations of liposomal active substance carriers for pharmaceutical, cosmetic and veterinary substances; cosmeceutical preparations for medical use; local anaesthetics, steroids; anti-inflammatory drugs; pharmaceuticals for the treatment of nail fungal infections; vaccines; immunotherapeutic vaccines; lipids for topical and parenteral use; creams, dispersions, lotions, ointments, gels, solutions, sprays, lacquers and film forming solution for the treatment of pain or inflammation; surfactants for use in the treatment of or prevention of cancer, infectious disease, fungal</p>
--------------------------------------	---------------	----	--

		<p>diseases, disease caused by parasites, eye disease, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, inherited disease, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases and reproductive system disorders, the treatment of inflammation, asthma, atopic eczema, dishydrotic hand eczema, plaque type psoriasis, seborrhoeic eczema, acne vulgaris, bronchospasm, atherothrombotic cardiovascular disorders, venous thrombotic disorders, pain, dysmenorrhea, hypercholesterolemia, hypertriglyceridemia, fatty acid metabolism, metal or other toxicity, Alzheimer's disease, gout or macular degeneration, such as AMD, or fungal infection and disorders related to fatty acid deficiencies.</p> <p>Class 10</p> <p>Surgical, medical and dental apparatus and instruments; artificial limbs, eyes and teeth; orthopaedic articles; suture materials; apparatus for carrying out diagnostic tests for medical purposes; syringes; injectors, medical thermometers, blood sugar meters; fibrin scaffolds, stents; x-ray machines; medical devices for topical use in the treatment of pain; molecular filtering devices for medical use; medical, veterinary and surgical apparatus, instruments and devices; inhalers; injection apparatus, instruments and devices; apparatus, instruments and devices for dispensing medical, surgical and veterinary preparations, dispersions, creams, powders, tablets and pills, instruments and devices for the administration of pain relief therapy and prophylaxis preparations and substances, parts and fittings for</p>
--	--	--

			<p>all of the aforesaid</p> <p>Class 42</p> <p>Scientific and technological services and research and design relating thereto, industrial analysis and research services; design and development of computer hardware and software, medical research; the provision of technical information on pharmaceutical products and services through an on-line computer network and research and design relating thereto; pharmaceutical research services; services for assessing the efficiency of pharmaceuticals.</p>
Pro Bono Bio Entrepreneur Limited	UK00003036003	UK	<p>Class 5</p> <p>Pharmaceutical preparations and substances; veterinary preparations and substances; veterinary preparations and pharmaceuticals in the fields of laminitis, debilitating joint diseases, bog spavin and bone spavin, bowed tendons, capped joints, curb (inflammation of the rear cannon bone below the point of hock), laminitis, navicular disease, osselets, ringbone, sesamoiditis, shoe boil, sidebone, speedy cut (namely striking of the inner lower side of the knee with the opposite limb), splints, sprains, stocking up, stringhalt,</p>

			<p>thoroughpin (swelling of the digital flexor tendon sheath), and windpuffs (swelling around the fetlock joint), arthritis and osteoarthritis, inflammation and diseases of the central nervous system; diagnostic preparations for veterinary use; topical and parenteral preparations of vesicles; chemical preparations in the form of vesicles for veterinary purposes; chemical membranes, chemical aggregates for veterinary purposes; preparations of arachidonic acids for veterinary purposes; anti-inflammatory drugs; pharmaceuticals for the treatment of hoof, talon and paw fungal infections; creams, dispersions, lotions, ointments, gels, solutions, sprays, lacquers and film forming solutions for the treatment of pain or inflammation, surfactants for use in the treatment of inflammatory diseases, diseases of the mouth, teeth, skin, hair and ear, eczema, psoriasis and pain.</p> <p>Class 10</p> <p>Medical devices for topical use in the treatment of pain; molecular filtering devices for veterinary use, veterinary devices for the treatment of laminitis and debilitating joint diseases, bog spavin and bone spavin, bowed tendons, capped joints, curb (inflammation of the rear cannon bone below the point of hock), laminitis, navicular disease, osselets, ringbone, sesamoiditis, shoe boil, sidebone, speedy cut (namely striking of the inner lower side of the knee with the opposite limb), splints, sprains, stocking up, stringhalt, thoroughpin (swelling of the digital flexor tendon sheath), and windpuffs (swelling around the fetlock joint), arthritis and osteoarthritis, inflammation and diseases of the central nervous system; veterinary instruments and devices for</p>
--	--	--	---

			<p>dispensing veterinary preparations, dispersions, creams, powders, tablets and pills; veterinary devices for the administration of pain relief, therapy and prophylaxis; parts and fittings for the aforesaid.</p> <p>Class 44</p> <p>Animal healthcare services; veterinary services, advisory services relating to the care of animals; hiring of veterinary instruments; veterinary advisory services; shoeing horses and maintaining horses' hooves; information services relating to veterinary pharmaceuticals; information services relating to the veterinary pharmaceutical industry; veterinary services including screening, diagnostic and testing services, Veterinary specialty services providing advanced medical and diagnostic services for animals; providing online information in the field of animals and pets, relating to animal healthcare and services; animal grooming; animal breeding</p>
Pro Bono Bio Entrepreneur Limited	EU013018957	UK	<p>Class 5</p> <p>Pharmaceutical preparations and substances; veterinary preparations and substances; veterinary preparations and pharmaceuticals in the fields of laminitis, debilitating joint diseases, bog spavin and bone spavin, bowed tendons, capped joints, curb (inflammation of the rear cannon bone below the point of hock), laminitis, navicular disease, osselets, ringbone, sesamoiditis, shoe boil, sidebone; veterinary preparations and pharmaceuticals in the fields of speedy cut (namely striking of the inner lower side of the knee with the opposite limb), splints, sprains, stocking up, stringhalt, thoroughpin (swelling of the digital flexor tendon sheath), and windpuffs</p>

		<p>(swelling around the fetlock joint), arthritis and osteoarthritis, inflammation and diseases of the central nervous system; diagnostic preparations for veterinary use, topical and parenteral preparations of vesicles; chemical preparations in the form of vesicles for veterinary purposes, chemical membranes; chemical aggregates for veterinary purposes; preparations of arachidonic acids for veterinary purposes, anti-inflammatory drugs; pharmaceuticals for the treatment of hoof, talon and paw fungal infections; creams, dispersions, lotions, ointments, gels, solutions, sprays, lacquers and film forming solutions for the treatment of pain or inflammation, surfactants for use in the treatment of inflammatory diseases, diseases of the mouth, teeth, skin, hair and ear, eczema, psoriasis and pain.</p> <p>Class 10</p> <p>Medical devices for topical use in the treatment of pain; molecular filtering devices for veterinary use; veterinary devices for the treatment of laminitis and debilitating joint diseases, bog spavin and bone spavin, bowed tendons, capped joints, curb (inflammation of the rear cannon bone below the point of hock), laminitis, navicular disease, osselets, ringbone, sesamoiditis, shoe boil, sidebone; veterinary devices for the treatment of speedy cut (namely striking of the inner lower side of the knee with the opposite limb), splints, sprains, stocking up, stringhalt, thoroughpin (swelling of the digital flexor tendon sheath), and windpuffs (swelling around the fetlock joint), arthritis and osteoarthritis, inflammation and diseases of the central nervous system; veterinary instruments and devices for dispensing veterinary preparations,</p>
--	--	---

			<p>dispersions, creams, powders, tablets and pills; veterinary devices for the administration of pain relief, therapy and prophylaxis; parts and fittings for the aforesaid</p> <p>Class 44</p> <p>Animal healthcare services; veterinary services; advisory services relating to the care of animals; hiring of veterinary instruments; veterinary advisory services; shoeing horses and maintaining horses' hooves; information services relating to veterinary pharmaceuticals, information services relating to the veterinary pharmaceutical industry; veterinary services including screening, diagnostic and testing services; Veterinary specialty services providing advanced medical and diagnostic services for animals; providing online information in the field of animals and pets, relating to animal healthcare and services; animal grooming; animal breeding.</p>
Pro Bono Bio Entrepreneur Limited	UK00003075153	UK	<p>Class 5</p> <p>Pharmaceutical preparations and substances, veterinary preparations and substances; veterinary preparations and pharmaceuticals in the fields of laminitis, debilitating joint diseases, bog spavin and bone spavin, bowed tendons, capped joints, curb (inflammation of the rear cannon bone below the point of hock), laminitis, navicular disease, osselets, ringbone, sesamoiditis, shoe boil, sidebone, speedy cut (namely striking of the inner lower side of the knee with the opposite limb), splints, sprains, stocking up, stringhalt, thoroughpin (swelling of the digital flexor tendon sheath), and windpuffs (swelling around the fetlock joint), arthritis and osteoarthritis, inflammation and diseases of the</p>

		<p>central nervous system; diagnostic preparations for veterinary use, topical and parenteral preparations of vesicles; chemical preparations in the form of vesicles for veterinary purposes; Chemical membranes for veterinary purposes ; chemical aggregates for veterinary purposes; preparations of arachidonic acids for veterinary purposes; anti-inflammatory drugs; pharmaceuticals for the treatment of hoof fungal infections; creams, dispersions, lotions, ointments, gels, solutions, sprays, lacquers and film forming solutions for the treatment of pain or inflammation; surfactants for use in the treatment of inflammatory diseases, diseases of the mouth, teeth, skin, hair and ear, eczema, psoriasis and pain</p> <p>Class 10</p> <p>Medical devices for topical use in the treatment of pain; molecular filtering devices for veterinary use; veterinary devices for the treatment of laminitis and debilitating joint diseases, bog spavin and bone spavin, bowed tendons, capped joints, curb (inflammation of the rear cannon bone below the point of hock), laminitis, navicular disease, osselets, ringbone, sesamoiditis, shoe boil, sidebone, speedy cut (namely striking of the inner lower side of the knee with the opposite limb), splints, sprains, stocking up, stringhalt, thoroughpin (swelling of the digital flexor tendon sheath), and windpuffs (swelling around the fetlock joint), arthritis and osteoarthritis, inflammation and diseases of the central nervous system; veterinary instruments and devices for dispensing veterinary preparations, dispersions, creams, powders, tablets and pills; veterinary devices for the administration of pain relief, therapy</p>
--	--	---

			<p>and prophylaxis; parts and fittings for the aforesaid.</p> <p>Class 44</p> <p>Animal healthcare services; veterinary services; advisory services relating to the care of animals; hiring of veterinary instruments; veterinary advisory services; shoeing horses and maintaining horses' hooves; information services relating to veterinary pharmaceuticals; information services relating to the veterinary pharmaceutical industry; veterinary services including screening, diagnostic and testing services; veterinary specialty services providing advanced medical and diagnostic services for animals; providing online information in the field of animals and relating to animal healthcare and services; animal grooming; animal breeding.</p>
Pro Bono Bio Entrepreneur Limited	UK00003082911	UK	<p>Class 3</p> <p>Toiletries, skin care preparations, face cleansers, cosmetic preparations for skin care, serum, beauty balms; skin balms, skin toners, exfoliators, eye masks, face masks, toners; skin cream, oils, lotions and sprays; skin conditioners, moisturisers, eye cream, eye gel, lip moisturisers, lip balm, hand cream, body lotions, body washes, foot balms, body scrubs; skin care kits, toiletry kits, essential oils, fragrances, soap, hair care preparations, dentifrices.</p> <p>Class 5</p> <p>Pharmaceutical preparations and substances, veterinary and sanitary preparations and substances; chemical preparations for pharmaceutical purposes; topical and parenteral preparations of vesicles; chemical preparations in the form of vesicles for medical and veterinary</p>

		<p>purposes; chemical membranes and chemical aggregates for medical and veterinary purposes; preparations of arachidonic acids; dispersions and dry preparations of liposomal active substances for use as a pharmaceutical, cosmetic and veterinary substance carrier; cosmeceutical preparations for medical use; local anaesthetics, lipids for topical and parenteral use, creams, dispersions, lotions, ointments, gels, solutions, sprays, lacquers, foams and film forming solution for the treatment of ocular conditions, subcutaneous conditions such as cellulitis, dermal conditions associated with all layers of the skin, superficial and deep; surfactants for use in the treatment of diseases affecting the immune system, inflammatory diseases, diseases of the skin, hair and ear, the treatment of pain and inflammation, rosacea and skin redness, atopic eczema, dishydrotic hand eczema, seborrhoeic eczema, pruritus and other skin irritations, plaque type psoriasis, acne vulgaris, breakouts, spots and other blemishes, bacterial, fungal and viral infections related to the skin and/or its secretions, male pattern baldness, the treatment of wrinkles, eye-bags, pigmentation disorders and other dermatological conditions caused by skin aging and other forms of damage or where skin supporting structures becomes weakened.</p> <p>Class 10</p> <p>Medical devices for topical use in the treatment of dermal conditions associated with all layers of the skin, superficial and deep; molecular filtering devices for medical use; medical, veterinary and surgical apparatus, instruments and devices; inhalers, injection apparatus,</p>
--	--	---

			instruments and devices, apparatus, instruments and devices for dispensing medical, surgical and veterinary preparations, creams, dispersions, lotions, ointments, gels, solutions, sprays, lacquers, foams, film forming solutions, tablets and pills, instruments and devices for the administration of skin disease and aging therapy and prophylaxis preparations and substances, parts and fittings for all of the aforesaid.
Pro Bono Bio Entrepreneur Limited	UK00003083506	UK	<p>Class 3</p> <p>Toiletries, skin care preparations, face cleansers, cosmetic preparations for skin care, serum, beauty balms; skin balms, skin toners, exfoliators, eye masks, face masks, toners, skin cream, oils, lotions and sprays; skin conditioners, moisturisers, eye cream, eye gel, lip moisturisers, lip balm, hand cream, body lotions, body washes, foot balms, body scrubs; skin care kits, toiletry kits, essential oils, fragrances, soap, hair care preparations, dentifrices.</p> <p>Class 5</p> <p>Pharmaceutical preparations and substances; veterinary and sanitary preparations and substances, chemical preparations for pharmaceutical purposes, topical and parenteral preparations of vesicles, chemical preparations in the form of vesicles for medical and veterinary purposes; chemical membranes and chemical aggregates for medical and veterinary purposes; preparations of arachidonic acids; dispersions and dry preparations of liposomal active substances for use as a pharmaceutical, cosmetic and veterinary substance carrier; cosmeceutical preparations for medical use; local anaesthetics, lipids for topical and parenteral use,</p>

		<p>creams, dispersions, lotions, ointments, gels, solutions, sprays, lacquers, foams and film forming solution for the treatment of ocular conditions, subcutaneous conditions such as cellulitis, dermal conditions associated with all layers of the skin, superficial and deep; surfactants for use in the treatment of diseases affecting the immune system, inflammatory diseases, diseases of the skin, hair and ear, the treatment of pain and inflammation, rosacea and skin redness, atopic eczema, dishydrotic hand eczema, seborrhoeic eczema, pruritus and other skin irritations, plaque type psoriasis, acne vulgaris, breakouts, spots and other blemishes, bacterial, fungal and viral infections related to the skin and/or its secretions, male pattern baldness, the treatment of wrinkles, eye-bags, pigmentation disorders and other dermatological conditions caused by skin aging and other forms of damage or where skin supporting structures becomes weakened.</p> <p>Class 10</p> <p>Medical devices for topical use in the treatment of dermal conditions associated with all layers of the skin, superficial and deep; molecular filtering devices for medical use; medical, veterinary and surgical apparatus, instruments and devices; inhalers; injection apparatus, instruments and devices, apparatus, instruments and devices for dispensing medical, surgical and veterinary preparations, creams, dispersions, lotions, ointments, gels, solutions, sprays, lacquers, foams, film forming solutions, tablets and pills; instruments and devices for the administration of skin disease and aging therapy and prophylaxis preparations and substances; parts</p>
--	--	---

			and fittings for all of the aforesaid.
Pro Bono Bio Entrepreneur Limited	UK00003088627	UK	<p>Class 3</p> <p>Toiletries, skin care preparations, face cleansers, cosmetic preparations for skin care. serum; beauty balms; skin balms, skin toners, exfoliators, eye masks, face masks, toners, skin cream, oils, lotions and sprays; skin conditioners, moisturisers, eye cream, eye gel, lip moisturisers, lip balm, hand cream, body lotions, body washes, foot balms, body scrubs; skin care kits; toiletry kits, essential oils, fragrances, soap, hair care preparations, dentifrices</p> <p>Class 5</p> <p>Pharmaceutical preparations and substances; veterinary and sanitary preparations and substances; chemical preparations for pharmaceutical purposes, topical and parenteral preparations of vesicles; chemical preparations in the form of vesicles for medical and veterinary purposes; chemical membranes and chemical aggregates for medical and veterinary purposes; preparations of arachidonic acids; dispersions and dry preparations of liposomal active substances for use as a pharmaceutical, cosmetic and veterinary substancecarrier; cosmeceutical preparations for medical use; local anaesthetics; lipids for topical and parenteral use; creams, dispersions, lotions, ointments, gels, solutions, sprays, lacquers, foams and film forming solution for the treatment of ocular conditions, subcutaneous conditions such as cellulitis, dermal conditions associated with all layers of the skin, superficial and deep; surfactants for use in the treatment of diseases affecting the immune system, inflammatory diseases, diseases of</p>

			<p>the skin, hair and ear, the treatment of pain and inflammation, rosacea and skin redness, atopic eczema, dishydrotic hand eczema, seborrhoeic eczema, pruritus and other skin irritations, plaque type psoriasis, acne vulgaris, breakouts, spots and other blemishes. bacterial, fungal and viral infections related to the skin and/or its secretions, male pattern baldness, the treatment of wrinkles, eye-bags, pigmentation disorders and other dermatological conditions caused by skin aging and other forms of damage or where skin supporting structures becomes weakened.</p> <p>Class 10</p> <p>Medical devices for topical use in the treatment of dermal conditions associated with all layers of the skin, superficial and deep; molecular filtering devices for medical use; medical, veterinary and surgical apparatus, instruments and devices; inhalers; injection apparatus, instruments and devices; apparatus, instruments and devices for dispensing medical, surgical and veterinary preparations, creams, dispersions, lotions, ointments, gels, solutions, sprays, lacquers, foams, film forming solutions, tablets and pills; instruments and devices for the administration of skin disease and aging therapy and prophylaxis preparations and substances; parts and fittings for all of the aforesaid.</p>
Pro Bono Bio Entrepreneur Limited	EU013931191	UK	<p>Class 3</p> <p>Toiletries, skin care preparations, face cleansers, cosmetic preparations for skin care, serum; beauty balms; skin balms, skin toners, exfoliators, eye masks, face masks, toners; skin cream, oils, lotions and sprays; skin conditioners, moisturisers, eye</p>

		<p>cream, eye gel, lip moisturisers, lip balm, hand cream, body lotions, body washes, foot balms, body scrubs; skin care kits; toiletry kits, essential oils, fragrances, soap, hair care preparations, dentifrices.</p> <p>Class 5</p> <p>Pharmaceutical preparations and substances, veterinary and sanitary preparations and substances; chemical preparations for pharmaceutical purposes; topical and parenteral preparations of vesicles; chemical preparations in the form of vesicles for medical and veterinary purposes; chemical membranes and chemical aggregates for medical and veterinary purposes; preparations of arachidonic acids; dispersions and dry preparations of liposomal active substances for use as a pharmaceutical, cosmetic and veterinary substance carrier; cosmeceutical preparations for medical use; local anaesthetics, lipids for topical and parenteral use, creams, dispersions, lotions, ointments, gels, solutions, sprays, lacquers, foams and film forming solution for the treatment of ocular conditions, subcutaneous conditions such as cellulitis, dermal conditions associated with all layers of the skin, superficial and deep, surfactants for use in the treatment of diseases affecting the immune system, inflammatory diseases, diseases of the skin, hair and ear, the treatment of pain and inflammation, rosacea and skin redness, atopic eczema, dishydrotic hand eczema, seborrhoeic eczema, pruritus and other skin irritations, plaque type psoriasis, acne vulgaris, breakouts, spots and other blemishes; surfactants for use in the treatment of bacterial, fungal and viral infections related to the skin and/or its</p>
--	--	---

		<p>secretions, male pattern baldness, the treatment of wrinkles, eye-bags, pigmentation disorders and other dermatological conditions caused by skin aging and other forms of damage or where skin supporting structures becomes weakened.</p> <p>Class 10</p> <p>Medical devices for topical use in the treatment of dermal conditions associated with all layers of the skin, superficial and deep; molecular filtering devices for medical use; medical, veterinary and surgical apparatus, instruments and devices; inhalers; injection apparatus, instruments and devices; apparatus, instruments and devices for dispensing medical, surgical and veterinary preparations, creams, dispersions, lotions, ointments, gels, solutions, sprays, lacquers, foams, film forming solutions, tablets and pills; instruments and devices for the administration of skin disease and aging therapy and prophylaxis preparations and substances; parts and fittings for all of the aforesaid</p>
Pro Bono Bio Entrepreneur Limited	EU014008916	<p>Class 5</p> <p>Pharmaceutical preparations and substances; veterinary preparations and substances; veterinary preparations and pharmaceuticals in the fields of laminitis, debilitating joint diseases, bog spavin and bone spavin, bowed tendons, capped joints, curb (inflammation of the rear cannon bone below the point of hock), laminitis, navicular disease, osselets, ringbone, sesamoiditis, shoe boil, sidebone, speedy cut (namely striking of the inner lower side of the knee with the opposite limb), splints; veterinary preparations and pharmaceuticals in the fields of sprains, stocking up, stringhalt,</p>

		<p>thoroughpin (swelling of the digital flexor tendon sheath), and windpuffs (swelling around the fetlock joint), arthritis and osteoarthritis, inflammation and diseases of the central nervous system; diagnostic preparations for veterinary use; topical and parenteral preparations of vesicles; chemical preparations in the form of vesicles for veterinary purposes, chemical membranes for veterinary purposes; chemical aggregates for veterinary purposes; preparations of arachidonic acids for veterinary purposes; anti-inflammatory drugs, pharmaceuticals for the treatment of hoof fungal infections; creams, dispersions, lotions, ointments, gels, solutions, sprays, lacquers and film forming solutions for the treatment of pain or inflammation; surfactants for use in the treatment of inflammatory diseases, diseases of the mouth, teeth, skin, hair and ear, eczema, psoriasis and pain</p> <p>Class 10</p> <p>Medical devices for topical use in the treatment of pain; molecular filtering devices for veterinary use; veterinary devices for the treatment of laminitis and debilitating joint diseases, bog spavin and bone spavin, bowed tendons, capped joints, curb (inflammation of the rear cannon bone below the point of hock), laminitis, navicular disease, osselets, ringbone, sesamoiditis, shoe boil, sidebone, speedy cut (namely striking of the inner lower side of the knee with the opposite limb), splints, veterinary devices for the treatment of sprains, stocking up, stringhalt, thoroughpin (swelling of the digital flexor tendon sheath), and windpuffs (swelling around the fetlock joint), arthritis and osteoarthritis, inflammation and diseases of the</p>
--	--	--


			<p>central nervous system, veterinary instruments and devices for dispensing veterinary preparations, dispersions, creams, powders, tablets and pills; veterinary devices for the administration of pain relief, therapy and prophylaxis; parts and fittings for the aforesaid.</p> <p>Class 44</p> <p>Animal healthcare services; veterinary services; advisory services relating to the care of animals, hiring of veterinary instruments; veterinary advisory services; shoeing horses and maintaining horses' hooves; information services relating to veterinary pharmaceuticals; information services relating to the veterinary pharmaceutical industry; veterinary services including screening, diagnostic and testing services; veterinary specialty services providing advanced medical and diagnostic services for animals; providing online information in the field of animals and relating to animal healthcare and services; animal grooming, animal breeding.</p>
--	--	--	---

EXECUTION of the Deed:

7/4

CHARGORS

SIGNED as a deed by JOHN MAYO,)
Director, duly authorised for and on behalf)
of Pro Bono Bio plc in the presence of:)



Witness's signature:




Witness's name
(in capitals):

JUSTIN BOWEN

Witness's address:



SIGNED as a deed by JOHN MAYO,)
Director, duly authorised for and on behalf)
of Pro Bono Bio Entrepreneur Limited)
in the presence of:)



Witness's signature:




Witness's name
(in capitals):

JUSTIN BOWEN

Witness's address:



SIGNED as a deed by JOHN MAYO,)
Director, duly authorised for and on behalf)
of Pro Bono Bio Group plc in the)
presence of:)



Witness's signature:



Witness's name
(in capitals):

JUSTIN BOWEN

Witness's address:




Re



Name: RICHARD WOLF - GARRAWAY

Duly authorised for and on behalf of


Leverton Licence Holdings Limited



Name: RICHARD WOLF - GARRAWAY

Duly authorised for and on behalf of


Pro Bono Bio International Trading Limited



Name: RICHARD WOLF - GARRAWAY

Duly authorised for and on behalf of

Sequessome Technology Holdings Limited



Name: RICHARD WOLF - GARRAWAY

Duly authorised for and on behalf of

Cantab Biopharmaceuticals Patents Limited

Name: RICHARD WOLF - GARRAWAY

Duly authorised for and on behalf of

PBB (Malta) Limited

LENDER

Knight Therapeutics Inc.

By:

Name:

Title.

Name:

Duly authorised for and on behalf of
PBB (Malta) Limited

LENDER

Knight Therapeutics Inc.

By:



Name: Jeffrey Kabanoff

Title: CFO